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 Abstract 
GABAA receptors (GABAARs) are a class of physiologically- and therapeutically-
important ligand-gated ion channels. These pentameric receptors occur in the brain with 
diverse subunit composition, which confers highly complex pharmacology to this 
receptor class. An impressive range of clinically-used therapeutics are known to bind to 
distinct sites found on GABAARs to modulate receptor function. Numerous experimental 
approaches have been used over the years to elucidate the binding sites of these drugs, 
but unequivocal identification is challenging due to subtype- and ligand-dependent 
pharmacology. This thesis focuses on two compounds with anxiolytic effects thought to 
be mediated via GABAARs. However, as the subunit requirement for their actions at 
GABAARs is poorly understood, we sought to investigate this using electrophysiological 
and mutational approaches on various human recombinant GABAAR subtypes expressed 
in Xenopus oocytes. 
 
2′MeO6MF 
2′-Methoxy-6-methylflavone (2′MeO6MF) is an anxiolytic flavonoid which has been 
shown to display GABAAR β2/3-subunit selectivity, a pharmacological profile similar to 
that of the general anaesthetic etomidate. Electrophysiological studies suggest that the 
full agonist action of 2′MeO6MF at α2β3γ2L GABAARs may mediate the flavonoid’s in 
vivo effects. However, we found variations in the relative efficacy of 2′MeO6MF 
(2′MeO6MF-elicited current responses normalised to the maximal GABA response) at 
α2β3γ2L GABAARs due to mixed receptor populations. To identify which receptor(s) 
underlie the variations observed, we conducted a systematic investigation of 2′MeO6MF 
 activity at all receptor combinations that could theoretically form (α2, β3, γ2L, α2β3, 
α2γ2L, β3γ2L and α2β3γ2L) in Xenopus oocytes using the two-electrode voltage clamp 
technique. We found that 2′MeO6MF activated non-α-containing β3γ2L receptors. In an 
attempt to establish the optimal conditions to express a uniform population of these 
receptors, we found that varying the relative amounts of β3:γ2L subunit mRNAs resulted 
in differences in the level of constitutive activity, the GABA concentration-response 
relationships, and the relative efficacy of 2′MeO6MF activation. Like 2′MeO6MF, 
general anaesthetics such as etomidate and propofol also showed distinct levels of relative 
efficacy across different injection ratios. Based on these results, we infer that β3γ2L 
receptors may form with different subunit stoichiometries, resulting in the complex 
pharmacology observed across different injection ratios. Moreover, the discovery that 
GABA and etomidate have direct actions at the α-lacking β3γ2L receptors raises 
questions about the structural requirements for their respective binding sites at 
GABAARs. 
 
Kavain 
Extracts from the pepper plant kava (Piper methysticum) are effective in alleviating 
anxiety in clinical trials. However, the molecular target(s) of the pharmacologically active 
constituents, kavalactones have not been established. GABAARs are assumed as the in 
vivo molecular target of kavalactones, but evidence to date is equivocal. In this study, we 
sought to determine the activity of kavain, the major anxiolytic kavalactone at human 
recombinant α1β2, β2γ2L, αxβ2γ2L (x = 1, 2, 3 and 5), α1βxγ2L (x = 1, 2 and 3) and 
α4β2δ GABAARs expressed in Xenopus oocytes using the two-electrode voltage clamp 
technique. We found that kavain positively modulated all receptors regardless of the 
subunit composition, but the enhancement was greater at α4β2δ GABAARs. The 
 benzodiazepine site antagonist flumazenil failed to block the action of kavain at α1β2γ2L 
receptors, supporting previous findings that kavalactones do not modulate GABAARs via 
the benzodiazepine binding site. As part of our efforts to investigate the interaction of 
kavain with other ligands on a receptor level, we found that kavain modestly inhibited the 
activity of general anaesthetics. Mutational studies showed that while α1M236W, 
β2M286W and β3N265M point mutations impaired general anaesthetics’ sensitivity, 
kavain’s modulation was only reduced by β3N265M. This finding suggests that kavain 
and general anaesthetics may share a common mechanism, but differ in their molecular 
determinants. As transgenic mice bearing the β3N265M point mutation are resistant to 
anaesthetic effects, we infer that the significant attenuation of kavain modulation with the 
introduction of this point mutation in vitro supports a direct kavain-GABAAR interaction, 
in contrast to the non-specific interaction previously suggested. 
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Chapter 1 
Introduction 
______________________________________ 
 
1.1. Ion channels and neuronal signalling 
The movement of ions into and out of neurons is a fundamental event that underlies 
neuronal signalling. One of the major pathways for ion transport is through ion channels, 
membrane-spanning proteins which form hydrophilic pores that selectively allow distinct 
ions to diffuse rapidly down the electrochemical gradient. These channels are not 
continuously open, but are activated or gated by specific stimuli such as voltage changes 
(voltage-gated ion channels), mechanical distortion of membrane (stretch-gated ion 
channels) and the binding of chemical agonists (ligand-gated ion channels; LGICs). Ion 
channels fluctuate between open and close states, with different transition states such as 
inactivation and desensitisation in between that help in the regulation of current flow 
across the membrane. 
 
In an unstimulated neuron, there is a difference in the ion concentrations across the cell 
membrane such that the electrical potential in the cytoplasm is more negative than the 
extracellular environment (resting membrane potential is typically around -60 mV). 
When an ion channel opens in response to a stimulus, the subsequent current flow alters 
the resting membrane potential, either by making it less negative (depolarisation) or more 
negative (hyperpolarisation). If a depolarising stimulus is sufficiently strong, different 
types of ion channels are sequentially activated, resulting in a self-propagating electrical 
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signal called an action potential which is used to communicate information from the 
peripheral nervous system (PNS) to the central nervous system (CNS), and vice versa. 
 
1.2. Fast synaptic transmission is mediated by 
neurotransmitter-gated ion channels 
Majority of neurons communicate via the release of neurotransmitters which bind and 
activate specific neurotransmitter-gated ion channels found on the postsynaptic neuron, 
resulting in fast synaptic conductances (< 10 ms). Depending on the type of receptors and 
the ionic conditions encountered, neurotransmitters can produce excitatory or inhibitory 
responses. Generally, synaptic excitation is mediated by the transmitter glutamate, 
whereas inhibition relies on γ-aminobutyric acid (GABA) and glycine.   
 
Glutamate activates cation-permeable NMDA- (N-methyl-D-aspartate), AMPA- (α-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate) and kainate-gated ion channels, 
resulting in Na+, K+ or Ca2+ ion influx into the postsynaptic neuron. The membrane 
depolarises as a result, and the probability of action potential generation increases. In the 
brain, GABA-mediated fast synaptic inhibition is achieved via the activation of anion-
permeable GABA type A receptors (GABAARs). The subsequent flow of Cl
- ions into the 
postsynaptic neuron leads to membrane hyperpolarisation and hinders action potential 
firing. Like GABAARs, glycine receptors are anion-permeable channels, and are found in 
great abundance in the spinal cord and brain stem. 
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1.3. GABAergic inhibition is essential for neuronal function 
Information relay from one neuron to the next is dependent on the use of glutamate to 
propagate excitatory signals. GABA-mediated (GABAergic) inhibition can be perceived 
simply as the force that counters excitation, but in reality, it participates in the 
coordination of neuronal activity in a highly complex manner. Specifically, GABAergic 
inhibition controls the rate of neuronal firing in response to increasing excitatory input 
(i.e., gain control) [1, 2], progressively recruits firing neurons to match the intensity of 
stimulus across a large dynamic range [3, 4], governs the stimulus selectivity of individual 
neurons (i.e., tuning) [5-8], generates and synchronises rhythmic changes in membrane 
potential (i.e., oscillations) which enable neurons to cooperate to convey signals to 
common downstream targets [9-11]. Given its fundamental regulatory roles, it is not 
surprising that GABAergic inhibition is implicated in various physiological processes 
such as neuronal development [12], learning [13-15], memory [16], circadian rhythm [17-
19], sleep [20, 21] and pain [22, 23], despite the fact that GABAergic neurons only make 
up approximately 30 % of all neurons [24].   
 
1.4. GABA synthesis, storage, release, reuptake and 
degradation 
In the GABAergic neurons, GABA is produced from the removal of a carboxyl group 
from glutamate, a process catalysed by the rate-limiting enzyme glutamic acid 
decarboxylase (GAD), which exists in two major isoforms, GAD65 and GAD67 (Figure 
1.1). GAD67 is constitutively active, and is responsible for the synthesis of a basal pool 
of GABA (> 90 % of GABA in the CNS), whereas GAD65 is activated when there is an 
increased demand during rapid inhibitory transmission. Disrupted GAD activity has been 
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shown to lead to detrimental consequences, with GAD67 knockout mice suffering from 
neonatal fatality [25, 26], and GAD65 knockout mice prone to epileptic seizures and 
anxiety despite appearing normal at birth [27, 28]. 
 
 
Figure 1.1. GABA synthesis, storage, release, reuptake and degradation. (1) In the 
presynaptic neuron, GABA is synthesised from glutamate by glutamic acid decarboxylase 
(GAD). (2) GABA is packaged into vesicles by the vesicular GABA transporters 
(VGAT). (3) GABA release into the synaptic cleft involves complex intracellular 
trafficking machineries which dock and fuse GABA-loaded vesicles with the presynaptic 
neuronal membrane. (4) GABA transporters (GATs) mediate the reuptake of GABA into 
the presynaptic neuron and surrounding glial cells to terminate GABAergic transmission. 
GABA recycled into the presynaptic neuron is mainly repackaged into synaptic vesicles 
for subsequent use. (5) In glial cells, GABA undergoes enzymatic degradation in the 
mitochondria.  
 
Once synthesised, GABA is loaded into synaptic vesicles by the vesicular GABA 
transporters (VGATs), a process which relies on the electrochemical gradient of protons 
across the vesicular membrane created by the H+-ATPase. The transport of GABA via 
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VGATs into vesicles is a prerequisite for GABA release into the synapses. Consistent 
with this critical role, when the VGAT gene was knocked out in mice, it was found that 
the postsynaptic GABA-mediated inhibitory currents were drastically reduced, and 
VGAT-deficient mice were found to die perinatally [29, 30]. 
 
GABA-loaded vesicles are accumulated in the presynaptic neuron terminals. The release 
of GABA into the synaptic cleft is stimulated by the arrival of an action potential at the 
presynaptic terminal, which leads to the opening of voltage-gated calcium channels, 
allowing the influx of Ca2+ ions. The elevated Ca2+ concentration then triggers a cascade 
of complex intracellular trafficking machineries which dock and fuse GABA-loaded 
vesicles with the presynaptic nerve terminal membrane [31, 32]. Following synaptic 
vesicle fusion, the contents of the vesicles are discharged into the synaptic cleft where 
GABA rapidly diffuses across to bind to a variety of GABA-gated receptors found on the 
postsynaptic neuron. The process of docking and fusing vesicles with the presynaptic 
nerve terminal membrane, and the subsequent release of GABA is referred to as 
exocytosis, which happens in an ultrafast manner (< 1 ms). Multiple receptors expressed 
presynaptically such as metabotropic GABA type B (GABAB) [33] and µ-opioid [34] 
receptors, ionotropic kainate [35] and nicotinic acetylcholine receptors [36, 37] are 
known to modulate the probability of GABA release. 
 
Termination of GABA-mediated inhibition is achieved primarily through the reuptake of 
GABA via GABA transporters (GATs) into the presynaptic neuron and neighbouring 
glial cells. GATs work as symporters to co-transport GABA with Na+ and Cl- ions, in 
other words, both GABA and the ions are transported in the same direction. The removal 
of GABA from the synaptic cleft serves to (1) govern its concentration and time spent in 
the synaptic cleft, thus preventing the excessive activation of GABA receptors, and (2) to 
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prevent GABA spillover to other synapses nearby, allowing individual synapses to work 
independently, thus ensuring synaptic specificity/fidelity. Four pharmacologically-
distinct isoforms of GATs have been identified thus far (GAT-1, GAT-2, GAT-3 and 
BGT-1). These transporters are distributed differentially, for instance, GAT-1 and GAT-
3 are predominantly expressed in neurons and glial cells respectively [38]. 
 
Most GABA molecules taken up into the presynaptic neuron are repackaged into synaptic 
vesicles for subsequent use, but some undergo enzymatic degradation. Unlike neurons, 
glial cells are not involved in synaptic transmission, and enzymatic degradation is the 
only fate for transported GABA in this cell type. In the mitochondria, GABA 
transaminase (GABA-T) is responsible for the conversion of GABA to succinate 
semialdehyde (SSA), which is then oxidised to succinic acid by SSA dehydrogenase. 
Succinic acid enters the Krebs cycle and gets converted into α-ketoglutarate, which is 
used in the synthesis of glutamate, the precursor of GABA. 
 
1.5. GABA and its receptors: GABAA, GABAB and GABAC 
GABA is a four-carbon, non-protein amino acid which exists predominantly in the 
zwitterionic form at physiological pH (Figure 1.2A). The backbone structure of GABA 
is made up of single carbon-carbon bonds with low energy barriers for rotations, allowing 
GABA to adopt diverse conformations ranging from fully extended, partially folded to 
fully folded (Figure 1.2B). The inherent flexibility of the GABA molecule is believed to 
be important for the differential actions of GABA across the large number of GABA-
recognising macromolecules such as enzymes, transporters as well as ionotropic and 
metabotropic receptors. Over the last four decades, the use of conformationally-restricted 
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GABA analogues has helped in the delineation of the structural requirements of the 
GABA binding sites on different proteins. 
 
 
Figure 1.2. GABA structure and conformations. (A) The chemical structure of GABA 
(unionised; top), and its physiological zwitterionic form (below). (B) The fully-extended 
(top), partially-folded (middle) and fully-folded (bottom) conformations of GABA. 
 
When GABA is released into the synaptic cleft, it binds and activates three distinct types 
of receptors known as GABAA, GABAB and GABAC receptors (GABAA/B/CRs). 
Structurally, GABAA and GABACRs are five-subunit protein complexes with a central 
channel pore selectively permeable to Cl- ions (Figure 1.3). However, the subunit 
composition of these receptors are very different. GABAARs are heteromeric (i.e., made 
up of more than one type of subunit), with 16 different subunit genes (α1–6, β1–3, γ1–3, 
δ, ε, θ and π) known to date. In contrast, GABACRs are homomeric receptors made up of 
one out of the three ρ (ρ1–3) subunits. However, there is evidence to suggest that these 
receptors can be heteromeric consisting of ρ1 and ρ2 [39] or ρ1 in combination with 
GABAA α1 and γ2 subunits [40].  
 
Unlike the ionotropic GABAA/CRs, GABABRs belong to the family of G protein-coupled 
receptors (GPCRs). GABABRs function as a heterodimer with a GABA-binding B1 
8 
 
 
subunit and a surface-expression mandatory B2 subunit. Each subunit has an extracellular 
domain, a seven-helix transmembrane domain and an intracellular domain which contains 
a coiled-coil helix that takes part in the dimerisation of GABABRs (Figure 1.3). The 
intracellular loops of the B2 subunit are coupled to guanidine-binding proteins (G-
proteins), and upon activation, trigger different effector mechanisms that result in the 
inhibition of presynaptic neurotransmitter release or membrane hyperpolarisation. 
 
 
Figure 1.3. GABAA, GABAB and GABACRs and their selective ligands. (Top) The 
physiological actions of GABA are mediated by GABAA, GABAB and GABACRs which 
are structurally, pharmacologically, and functionally different. GABAA and GABACRs 
are pentameric Cl- ion channels, whereas GABABRs are dimeric metabotropic receptors 
coupled to G-proteins. Following GABA binding, GABAA and GABACRs are activated 
and the subsequent Cl- influx causes membrane hyperpolarisation and reduced neuronal 
excitability. The inhibitory actions of GABABRs are dependent on the G-proteins 
downstream effector mechanisms which lead to the inhibition of neurotransmitter release 
or the gating of ion channels that result in membrane hyperpolarisation. (Bottom) The 
chemical structures of selective ligands for different types of GABA receptors.  
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Pharmacologically, GABAARs are conventionally defined by their selective inhibition by 
the competitive antagonist bicuculline and modulation by benzodiazepines and 
barbiturates. GABABRs are activated by the GABA analogues (R)-baclofen and are 
competitively antagonised by (R)-phaclofen and (R)-saclofen. GABACRs are insensitive 
to bicuculline and (R)-baclofen, are selectively activated by the conformationally-
restricted GABA analogue cis-aminocrotonic acid (CACA), and are inhibited by the 
competitive inhibitor (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA). 
The unique pharmacological profile of GABACRs has prompted its separation from 
GABAA and GABABRs. Notably, an International Union of Pharmacology (IUPHAR) 
committee has classified GABACRs as a ‘specialised set’ of GABAARs and 
recommended against the use of the term ‘GABAC’ [41]. However, for the purpose of 
this thesis, ‘GABAC’ is used to describe the specific category of bicuculline- and (R)-
baclofen-insensitive, ρ-containing GABA receptors. 
 
GABAARs are the most widespread GABA receptors in the CNS, facilitating fast 
inhibitory responses (< 10 ms) in the regulation of neuronal excitability. These receptors 
are highly concentrated on postsynaptic neuronal membrane, but they are also expressed 
extrasynaptically and presynaptically (Figure 1.1). The differential subcellular 
localisation of GABAARs involves specific scaffolding proteins such as gephyrin [42, 43] 
and collybistin [44] for synaptic and radixin [45] for extrasynaptic receptor anchoring. 
Like GABAARs, GABACRs are also involved in fast inhibitory transmission, but these 
receptors are more restricted in their topographical distribution, being highly enriched in 
brain areas related to the visual pathways such as the retina, thalamus and superior 
colliculus. The subcellular localisation mechanisms of GABACRs also appears to be 
different from GABAAR, with microtubule-associated protein 1B (MAP-1B) shown to 
specifically localise GABACRs at inhibitory synapses [46]. In contrast to GABAA/CRs, 
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GABABRs are involved in slow, prolonged inhibitory transmission that happens over the 
timescale of sub-seconds to minutes. GABABRs are widely distributed in the CNS, and 
are found pre-, post- and extrasynaptically (Figure 1.1). Presynaptic GABABRs can act 
as feedback autoreceptors to inhibit the release of GABA, or as heteroreceptors to inhibit 
glutamate release in nearby excitatory synapses. These effects are achieved either through 
Gαi/o inhibiting adenylyl cyclase which interferes with vesicle fusion and release, or Gβγ 
inhibiting voltage-gated calcium channels, preventing Ca2+-dependent neurotransmitter 
release [47]. Postsynaptic GABABRs can be found at synaptic and extrasynaptic sites. 
These receptors contribute to membrane hyperpolarisation via the activation of inwardly 
rectifying K+ channels which allows K+ ions to flow out of the cell. 
 
1.6. GABAARs: Physiological and clinical significance 
As the main mediator of GABAergic inhibition in the CNS, GABAARs represent a class 
of physiologically- and clinically-important receptors. Several lines of evidence support 
this notion. The mutation or deletion of various genes encoding for GABAAR subunits in 
mice is highly disruptive to the normal phenotype, causing developmental defects, 
sensorimotor dysfunction, hypersensitive behaviour, anxiety, epilepsy and/or reduced 
lifespan [48-51]. In humans, aberrant GABAAR trafficking, expression and/or gating 
effects have been implicated in autism [52], schizophrenia [53] and a range of idiopathic 
epileptic syndromes [54]. Genetic association studies have also linked GABAAR subunit 
genes with alcohol dependence [55], eating disorder outcomes [56], autism [57, 58] and 
bipolar disorders [59, 60]. Further evidence comes from the successful clinical utilisation 
of GABAAR modulators in the treatment of CNS-related disorders such as insomnia, 
anxiety and epilepsy, as well as in the induction of anaesthesia in surgical patients. While 
clinically useful, the misuse of these drugs poses risks of dependence, addiction, abuse 
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and life-threatening conditions associated with overdose or withdrawal. Understanding 
the functions of GABAARs and the underlying mechanisms of the clinical and undesirable 
effects of GABAAR-targeting drugs to improve the selectivity and safety of these 
therapeutics are topics of intensive research. The properties of GABAARs are also the 
focus of this thesis. 
  
1.7. Architecture of GABAARs and other pentameric LGICs 
The neurotransmitter-gated ion channels can be divided into three main structural classes: 
the trimeric P2X receptor family, the tetrameric glutamate receptor family and the 
pentameric LGIC (pLGIC) superfamily. GABAARs are a member of the pLGIC 
superfamily which includes the nicotinic acetylcholine receptors (nAChRs), 5-
hydroxytryptamine type 3 receptors (5-HT3Rs) and glycine receptors. The term ‘Cys-loop 
receptors’ has also been used to describe pLGICs due to a highly conserved 13-amino-
acid loop found in the extracellular domain which is connected by a disulphide bridge 
between two cysteine (Cys) residues. This characteristic Cys-loop is only found in 
eukaryotic pLGICs but not in their prokaryotic counterparts.  
 
Due to the inherent technical challenges associated with the overexpression, 
solubilisation, purification and crystallisation of mammalian pLGICs, the initial 
understanding of their three-dimensional structures was inferred from other homologues 
including the acetylcholine binding protein (AChBP) from the snail Lymnaea stagnalis 
[61], the heteromeric nAChR from the Torpedo marmorata electric organ [62], the 
bacterial Erwinia chrysanthemi LGIC (ELIC) [63] and Gloeobacter violaceus LGIC 
(GLIC) [64], and the Caenorhabditis elegans glutamate-gated chloride channel α 
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homopentamer (GluClα) [65]. More recently, X-ray crystal structures of a mouse 5-
HT3AR [66] and a human GABAAR [67] have been reported. Collectively, these studies 
reveal a similar overall architecture among these receptors. Each receptor subunit has an 
extracellular domain (ECD), a transmembrane domain (TMD) and an intracellular 
domain (ICD) which is absent in ELIC, GLIC and GluClα (Figure 1.4). The ECD is 
mostly made up of β sheets and contains agonist binding site, the TMD consists of the 
pore-forming α-helices and the structurally variable ICD is involved in receptor assembly, 
trafficking and clustering.  
 
 
Figure 1.4. Conserved overall architecture of pLGICs. Published structures of the 
soluble AChBP from the snail Lymnaea stagnalis (PDB: 1I9B) which is homologous to 
the ECD of nAChRs, the heteromeric nAChR from the Torpedo marmorata electric organ 
(PDB: 2BG9), the bacterial homologues ELIC (PDB: 2VL0) and GLIC (PDB: 3EAM), 
mouse 5-HT3AR (PDB: 4PIR) and human GABAAR (PDB: 4COF) show three distinct 
domains: an extracellular domain (ECD; red), a transmembrane domain (TMD; blue) and 
an intracellular domain (ICD; green) which is absent in ELIC, GLIC and GluCl. The 
resolutions (in Å) are indicated above individual structures.  
 
Besides providing structural details, these published receptor structures are also useful 
models to study various ligand binding sites, the different transition states underlying 
channel gating, and the mechanism of ion permeation through the channel pore [68]. For 
instance, molecular dynamics simulation using the closed-pore ELIC and the open-pore 
GLIC and GluClα crystal structures has allowed for the modelling of structural events 
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which unfold at distinct receptor states [69, 70]. However, this information has limited 
application due to the low sequence identities of these structures.  
 
For the interest of this thesis, the crystal structure of the β3 homomeric GABAAR obtained 
at 3 Å resolution will be described in more detail [67]. This receptor subtype is unlikely 
to be physiologically relevant, but its functional expression in heterologous systems is 
well known, and has been used as a model to study heteromeric GABAARs [71-77]. The 
receptor stands approximately 110 Å in height when viewed parallel to the membrane 
(Figure 1.5A). The five subunits assemble in a doughnut-like shape with a diameter 
around 80 Å, when viewed from the extracellular space, down the channel pore (Figure 
1.5B). The large ECD (~65 Å) of each subunit is made up of an N-terminal α-helix 
followed by a β-sandwich core with ten anti-parallel β-sheets (Figure 1.5C). The TMD 
consists of four membrane-spanning α-helices (M1–M4), with the M2 helices of all five 
subunits arranging themselves to form a tapered ion-conducting pore (Figure 1.5 B and 
C). The outermost M4 helix harbours the C-terminus on the extracellular end. The ICD 
contains a small M1–M2 loop and a much larger M3–M4 loop (G333–N446; residue 
numbering follows sequence of P28472 in UniProt) which was replaced with a 7-amino-
acid linker for the crystallisation of this structure (Figure 1.5C).  
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Figure 1.5. The crystal structure of a human β3 homomeric GABAAR (PDB: 4COF). 
(A) Cartoon representation of GABAAR viewed parallel to the membrane, coloured 
according to secondary structures (α-helices are in red except for the pore-forming helices 
(orange), β-sheets are in blue). (B) Left, GABAAR viewed from the extracellular space, 
with the five subunits labelled 1–5. Right, Transmembrane region of GABAAR, with the 
ECDs simplified as blue ovals for clarity. The arrangement of the four TMDs (M1–M4), 
the C-terminus (purple circles), and the M2–M3 loop (green) are illustrated. (C) Topology 
of a single subunit of GABAAR, rainbow coloured from the N-terminus (red) to the C-
terminus (purple). The β-sheets of the ECD, the α-helices of the TMDs, the characteristic 
Cys-loop and other relevant loops are indicated. Note: the intracellular M3-M4 loop 
(G333–N446) was replaced with a 7-amino-acid linker for crystallisation. Figures were 
prepared using Maestro, v. 9.5.014, Schrӧdinger, LLC. 
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1.8. GABAAR assembly: selective subunit oligomerisation 
Human genome sequencing has identified at least 16 GABAAR subunit genes (α1–6, β1–
3, γ1–3, δ, ε, θ and π), excluding the ρ subunits (ρ1–3). Given the heteromeric nature of 
GABAARs in vivo, this long list of subunits, together with the splice variants of some of 
the subunits (e.g., alternate splicing of precursor GABAA γ2 mRNA results in two splice 
variants, a short (γ2S) and a long (γ2L) variant) allow for an enormous range of 
theoretically possible subunit combinations. However, experimental evidence suggests 
that only a few dozen combinations exist in vivo (see section 1.9), indicating that 
GABAAR assembly is a selective, and not a random process. A hierarchical assembly 
mechanism has been proposed, in which certain subunits are preferred over others to form 
dimeric intermediates that ultimately assemble into pentameric complexes [78]. 
  
Different methods have been used to define the rules underlying receptor assembly. In 
concert, data obtained using functional, immunoimaging and sucrose gradient 
centrifugation techniques suggest that both α and β subunits are obligatory for the surface 
expression of fully functional pentameric receptors in heterologous cell systems [79-82]. 
The additional third γ subunit has been shown to enhance the efficiency of receptor 
assembly [81]. In contrast, the recombinant expression of individual α, β and γ subunits, 
and the α+γ and β+γ combinations mainly yielded di-, tri- and tetrameric oligomers which 
were retained in the endoplasmic reticulum [80, 83]. There are a few notable exceptions, 
however, with the homomeric β1 and β3 and the heteromeric β3γ2 receptors expressing 
readily in heterologous systems [72-74, 76, 84]. 
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Amino acid residues important for assembly have been identified in several studies using 
the chimeric receptor and site-directed mutagenesis approaches (reviewed in [78]). These 
residues are found mainly in the ECD, and to a lesser extent in the intracellular M3-M4 
loop. In accordance with these data, the β3 GABAAR crystal structure revealed extensive 
energetically favourable interactions such as hydrogen bonds, salt bridges and van der 
Waals forces along the interfaces between subunit ECDs [67]. Disruption to these 
interactions could affect receptor assembly, and may be the reason for impaired GABAAR 
surface expression with epilepsy-associated mutations found in the N-terminal regions 
such as β3G32R and γ2R43Q [85-87]. 
 
While considerable insights have been provided by these studies, the molecular 
determinants could not be firmly established for several reasons. Firstly, these 
determinants differ depending on the partner subunits. For example, four residues in the 
ECD of the β3 subunit (G171, K173, E179 and R180) have been identified to be critical 
for the assembly of β3 and β3γ2 receptors [73]. However, they are not compulsory for the 
assembly of αβ receptors. In another study that investigated the role of the N-terminal 
regions in the expression of α1β2γ2 GABAARs, subunit-specific contributions to receptor 
assembly were found [88]. When deleted, the N-terminus of the α1 subunit had the most 
prominent effect on the expression of α1β2γ2 receptors, whereas deletion in similar 
regions of the β2 and γ2 subunits had minimal effect on surface expression. Second, 
multiple residues may be involved in oligomerisation with the same neighbouring subunit 
[89]. As such, when a putative binding residue is mutated and has no effect on receptor 
expression, it does not necessarily indicate no participation in intersubunit linking. 
Conversely, an expression-impairing mutation does not validate its significance in 
subunit oligomerisation, as the residue may indirectly contribute to this process (e.g., by 
stabilising interacting regions). All in all, GABAAR assembly is a highly complex, multi-
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step process which involves subunit-specific determinants that govern the subunit 
composition of GABAARs found natively.     
 
1.9. Multiple subtypes, locations and actions of GABAARs 
In recent years, it has become evident that the multiplicity in GABAAR subunit 
composition (or subtypes) is one of the main reasons for the heterogeneity observed in 
their cellular and subcellular distributions, biophysical characteristics, pharmacological 
properties, in addition to physiological functions [90-92]. Furthermore, the subunit 
composition of GABAARs is plastic. Alterations in brain GABAAR subtypes have been 
reported under various developmental and pathological conditions [93-95]. As such, 
answering the question “which GABAAR subtypes actually occur in vivo?” is essential to 
understanding the diverse roles played by GABAergic inhibition. 
 
Currently, existing experimental techniques are unable to unequivocally identify 
GABAAR subunit composition in neurons. To help determine the likelihood of a receptor 
subtype being expressed physiologically, the IUPHAR committee has introduced five 
classification criteria [41]. Briefly, (1) the expression and co-assembly of the subunit 
proteins of a receptor candidate must be demonstrated in heterologous systems, along 
with (2) the characterisation of its biophysical and pharmacological properties. In the 
brain, (3) the subunit mRNAs or proteins should co-localise on the cellular and 
subcellular levels, and (4) the co-precipitation of these subunits would provide stronger 
evidence. More importantly, (5) a receptor candidate has to show unique functional 
characteristics that match those of the recombinant receptor subtype, and disruption to 
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the expression of this receptor subtype in genetically engineered mice should lead to 
altered receptor responses and behavioural profile. 
 
A working list of native GABAAR subtypes was proposed following stringent 
consideration of the criteria discussed (Table 1.1). These receptors are categorised as 
“identified”, “existence with high probability” or “tentative”. Evidence from 
immunochemical, pharmacological and genetic studies collectively indicate that the 
majority of GABAARs are composed of α, β and γ2 subunits in the CNS. The α1β2γ2 
subtype is the most prevalent isoform (approximately 50–60 % of all GABAARs), and are 
expressed in almost all brain regions. The γ2 subunit also co-assembles with other α and 
β variants in the brain, but these receptors are found in considerably less abundance and 
are restricted in their regional (e.g., α5-containing receptors are expressed in high density 
in hippocampus) and cellular (e.g., the α2β3γ2 and α3β3γ2 subtypes are highly enriched 
in hippocampal pyramidal neurons and cholinergic neurons of the basal forebrain, 
respectively) distributions.  
 
Table 1.1. The working list of native GABAAR subtypes categorised based on the 
strength of evidence proposed by Olsen and Sieghart (2008) [41]. 
Identified High probability Tentative 
α1β2γ2 α1β3γ2 αβγ1 
α2βγ2 α1βδ αβγ3 
α3βγ2 α5β3γ2 αβθ 
α4βγ2 αβ1γ/αβ1δ αβε 
α5βγ2 αβ αβπ 
α6βγ2 α1α6βγ/α1α6βδ αxαyβγ2a 
α4β2/3δ   
α6β2/3δ   
a αxαy represents two different α subunit isoforms (α1–6). 
 
Extrasynaptic 
Synaptic 
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In addition to the region- and cell-specific expression patterns, these receptors also show 
distinct subcellular localisation. The α1βγ2, α2βγ2 and α3βγ2 isoforms are typically 
found postsynaptically, whereas the α4βγ2, α5βγ2 and α6βγ2 isoforms are found 
extrasynaptically (Figure 1.1). In contrast, the δ subunit which preferentially assembles 
with the α6 and β2/3 subunits in the cerebellar granule cells [96], and with the α4 and 
β2/3 subunits in the forebrain [97], are exclusively expressed at extrasynaptic sites. Due 
to their proximity to the site of vesicle release, synaptic GABAARs are exposed to 
saturating GABA concentrations (~1–3 mM) that diffuse away from the synaptic cleft 
rapidly (clearance time < 1 ms) [98, 99]. This transient activation of synaptic GABAARs 
is responsible for phasic inhibition, a form of fast, point-to-point synaptic communication 
used to control the flow of specific signals. Extrasynaptic GABAARs, on the other hand, 
are randomly activated by low levels of ambient GABA (low micromolar range) which 
has escaped from the synaptic cleft on the same or nearby neurons. These receptors are 
persistently activated, thus provide a basal inhibitory conductance, termed tonic 
inhibition, which is believed to be important in the regulation of the overall excitability 
in the brain [91]. Synaptic and extrasynaptic GABAARs are equipped with distinct 
properties that facilitate their unique roles in their local environments. For example, δ 
subunit-containing receptors display characteristics such as higher GABA affinity, 
minimal desensitisation and longer channel open time, which are ideal for continual 
activation with sustained exposure to low levels of GABA [100]. Synaptic αβγ isoforms 
have lower GABA sensitivity, and rapid activation and desensitisation kinetics, making 
them well suited to mediate responses of the phasic vesicular release of GABA. 
 
Contrary to the belief that binary αβ combination has no physiological relevance, there is 
ample evidence suggesting that these receptors are highly probable to be found in vivo. 
The defining characteristics of these receptors such as low conductance states and high 
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sensitivity to Zn2+ inhibition have been detected in single-channel recordings conducted 
in rat neurons [101-103]. Besides that, receptors consisting only of α and β subunits have 
also been immunoprecipitated from brain membranes derived from normal or mutant 
rodents [48, 104-106]. The exact α and β isoforms that make up these receptors remains 
unclear, but they are thought to constitute a small portion of GABAARs, likely to be 
expressed at extrasynaptic sites in the brain [103]. To add to the diversity, GABAARs 
comprised of different types of α subunits (αxαyβγ2) have also been detected in the CNS 
[41], with high prevalence suggested in the spinal cord [107]. Other combinations that 
incorporate the minor subunits (γ1, γ3, θ, ε or π) are likely to occur in vivo, but more 
evidence is required to confirm their presence. It is expected that the list of native 
GABAAR subtypes will expand as the identification techniques continue to improve over 
time.  
 
1.10.   Subunit stoichiometry and arrangement of GABAARs 
Theoretically, a pentameric GABAAR composed of three types of subunits (e.g., αβγ) will 
have 6 configurations with different number of subunits (1α:1β:3γ, 2α:1β:2γ, 3α:1β:1γ, 
1α:2β:2γ, 1α:3β:1γ and 2α:2β:1γ). A greater number of unique configurations arises when 
the spatial orientation of these subunits is taken into consideration. For instance, a 
receptor with a 2α:2β:1γ subunit stoichiometry can have up to six different arrangements 
of γ-α-α-β-β, γ-α-β-α-β, γ-α-β-β-α, γ-β-β-α-α, γ-β-α-β-α and γ-β-α-α-β in a counter-
clockwise direction around the pore when viewed from the extracellular side. These 
configurations vary in the number and type of subunit interfaces, and as almost all known 
ligand binding sites are located interfacially, establishing the physiologically relevant 
configuration(s) is a prerequisite to understanding the mechanisms of receptor activation 
and modulation.  
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Numerous approaches including mutagenesis [108, 109], subunit counting in 
combination with immunoprecipitation [81] and fluorescence energy transfer microscopy 
[110] have been used to determine the stoichiometry of GABAARs. There are limitations 
associated with each technique, but in combination, these studies support a 2α:2β:1γ 
stoichiometry for αβγ receptors (Figure 1.6). The subunit arrangement of this receptor 
subtype has also been elucidated with the help of different concatenated constructs, i.e., 
GABAAR subunit genes fused in tandem with a linker of optimised length joining the C-
terminus of a preceding subunit to the N-terminus of a following subunit. These subunits 
are expressed as a single polypeptide with predetermined orientation, thus constraining 
the stoichiometry and arrangement of receptors expressed. The combination of various 
di- and trimeric concatemers suggests that only the γ-β-α-β-α arrangement (Figure 1.6; 
read counter-clockwise when viewed from the extracellular space) yields receptors with 
similar pharmacological and kinetic properties established in receptors assembled from 
free subunits [111-113]. However, the ambiguity remained whether these constructs were 
sufficient to force the receptors to assemble in the expected arrangement [114]. To 
address this issue, the pentameric γ-β-α-β-α concatemer was generated, and functional 
characterisation of this construct supports the findings from other studies [115]. It is worth 
noting that most of the studies mentioned have been conducted on the most prevalent 
subtype α1β2γ2, and it is presumed that all αβγ2 subtypes share the same subunit 
stoichiometry and arrangement. 
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Figure 1.6. Model structures of the ternary αβγ and binary αβ GABAARs 
demonstrating their respective subunit stoichiometry and arrangement. (A) The 
most prevalent native GABAAR subtype αβγ has a stoichiometry of 2α:2β:1γ, arranged 
γ-β-α-β-α counter-clockwise around the pore when viewed from the extracellular side. 
(B) The binary αβ receptors have been shown to assemble in two different stoichiometries 
of 2α:3β or 3α:2β, with a β-β-α-β-α or α-β-α-β-α arrangement respectively. 
 
In the case of the binary αβ receptors, concatemers with stoichiometry of either 2α:3β or 
3α:2β (Figure 1.6), but never both in the same study, form functional receptors with wild 
type-like properties [111, 113, 116]. It remains unclear whether one stoichiometry 
predominantly forms or both stoichiometries co-exist when these subunits are allowed to 
assemble freely. For δ-containing receptors, the accurate determination of the exact 
number and arrangement of the subunits is hindered by the promiscuous assembly 
properties of the δ subunit. Several studies suggest αβδ receptors share similar 
stoichiometry and arrangement as αβγ receptors, with the δ subunit replacing the γ subunit 
(2α:2β:1δ; δ-β-α-β-α) [117, 118]. However, 1α:1β:3δ, 1α:2β:2δ, 1α:3β:1δ and 2α:1β:2δ 
stoichiometries have also been detected with the subunit-counting and concatemer 
strategies [119-121]. To make things more complicated, the δ subunit is flexible in its 
positioning in the pentameric complex, producing receptors with distinct pharmacological 
properties [119, 121]. Similar promiscuity has also been observed with the ε subunit, 
which co-assembles with α and β subunits to form the αβε subtype with potential 
stoichiometries of 2α:2β:1ε and 2α:1β:2ε or with α, β and γ subunits to form the 
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quaternary αβγε subtype with multiple arrangements [122, 123]. Less is known about the 
stoichiometry and arrangement of receptors containing the θ and π subunits. 
 
1.11.   Pharmacology of GABAARs 
GABAARs have been described as the most complicated member of the superfamily of 
LGICs for the plethora of receptor subtypes and the rich pharmacology. The orthosteric 
GABA binding sites aside, it has been estimated that there are more than 10 potential 
ligand binding sites which are distributed at various locations throughout the receptor 
(Figure 1.7). A range of ligands such as benzodiazepines, barbiturates, anaesthetics, 
neurosteroids and convulsants can bind to distinct allosteric (non-orthosteric) sites to 
exert their physiological or clinical effects by influencing GABAAR function, either by 
causing or stabilising conformational changes in the receptor. Some of these sites are 
found at specific receptor subtypes, which define the unique pharmacological signatures 
of these receptors. The properties of the GABA binding sites and several well-studied 
allosteric binding sites are discussed below. 
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Figure 1.7. Schematic illustration of an αβγ GABAAR highlighting the orthosteric 
and allosteric binding sites. For the purpose of discussion, the approximate binding site 
locations are indicated by the prototype ligands. The principal (+) and complementary (‒
) faces of each subunit are also labelled.  
 
1.11.1.   GABA binding sites: extracellular β+α‒ interfaces  
A common feature of Cys-loop receptors is that the neurotransmitter binding pocket is 
located at the extracellular interface between two adjacent subunits. Each subunit 
contributes three (in some cases four) non-contiguous regions that form the binding site. 
By convention, the principal (+) face of the neurotransmitter binding site is made up of 
three loops (named loop A, B and C) and the complementary (‒) face has three β-strands 
and/or one loop (loop D, E, F and/or G; Figure 1.8A) [124]. For GABAARs, the β and α 
subunits bear the principal and complementary components of the GABA binding site 
respectively. In the most prevalent αβγ subtypes (2α:2β:1γ; γ-β-α-β-α), there are two 
GABA binding sites per receptor at the β+α‒ interfaces (Figure 1.7). Channel opening 
occurs with GABA occupying just one site, but the probability increases greatly when 
both sites are engaged [125-127]. These identical sites contribute asymmetrically to 
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receptor activation, a phenomenon which has been tentatively correlated with the binding 
sites assuming different conformations depending on their flanking subunits (one site sits 
between γ and β, the other sits between α and γ; Figure 1.7) [127]. The existence of other 
GABA binding interfaces consisting of the promiscuous δ subunit has also been proposed, 
but the molecular details of these sites are poorly understood [128]. 
 
 
Figure 1.8. Homology model of the GABA binding site at α1β2γ2 receptors. (A) The 
GABA binding site is located at the β+α‒ extracellular interface. The principal (loop A, 
B and C) and the complementary (loop D, E and F) components which form the binding 
pocket are highlighted in different colours. (B) GABA (green; ionised form) binding 
mode predicted by induced fit docking. Residues on both the β and α subunits which are 
implicated in GABA binding are indicated. Figures were taken from Bergmann et al. 
(2013) [129].     
 
Mutational, radioligand binding and photoaffinity labelling studies have identified 
residues with aromatic, hydroxylated and charged side chains on both the α and β subunits 
that are critical determinants in GABA sensitivity [130, 131]. It is currently inconclusive 
how these residues are located spatially to interact with GABA, but homology modelling 
has shed some light on the GABA binding mode. In 2013, Bergmann et al. created a 
model of the α1β2γ2 GABAAR based on the C. elegans GluClα and ELIC crystal 
structures [129]. When docked into the orthosteric binding site, GABA forms (1) salt 
bridges with α1Arg66 and β2Glu155, (2) hydrogen bonds with α1Thr129 and β2Thr202, 
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and (3) cation-π interaction with β2Tyr205 (Figure 1.8B). These predictions are in good 
agreement with experimental evidence, but crystal structures of GABA-bound GABAARs 
will be necessary for validation. 
 
Besides GABA, other structurally similar chemicals can access the orthosteric binding 
sites to elicit distinct functional responses. Some prototypical ligands include agonists 
muscimol and isoguvacine, partial agonists THIP/gaboxadol and P4S, and competitive 
antagonists bicuculline (Figure 1.3) and gabazine (Figure 1.9). The classification of 
ligands as agonists or partial agonists is not absolute, and is relative to the function of 
GABA, which is dependent on receptor subtype. For instance, GABA is known to act as 
a partial agonist at αβδ receptors, exhibiting higher affinity and lower intrinsic efficacy, 
unlike its full agonist activity at αβγ receptors [132, 133]. Such functional difference has 
resulted in the agonist muscimol and partial agonist THIP (at αβγ receptors) to exhibit 
superagonism (higher maximal efficacy than GABA) at αβδ receptors [134, 135].    
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Figure 1.9. Chemical structures of various classes of ligands that bind to the 
orthosteric and allosteric binding sites at GABAARs. 
 
1.11.2.   Benzodiazepine binding sites 
1.11.2.1.  High-affinity site: extracellular α+γ‒ interface 
Homologous to the β+α‒ GABA binding sites, a structurally-related pocket exists at the 
extracellular α+γ‒ interface (Figure 1.7). This allosteric site is commonly referred to as 
the benzodiazepine binding site, named after the prototype drugs. Benzodiazepines do not 
directly activate GABAARs, but they are able to modulate receptor function. 
Benzodiazepine site agonists (e.g., diazepam; Figure 1.9) potentiate GABAARs to 
produce clinically useful effects such as sedation (for insomnia), anxiolysis (for anxiety), 
anticonvulsant (for epilepsy), myorelaxant (for muscle spasms) and amnesia (for invasive 
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medical procedures). Conversely, benzodiazepine site inverse agonists (e.g., DMCM) 
inhibit GABAARs to exert anxiogenic, convulsant and memory-enhancing effects. 
Benzodiazepine site competitive antagonists (e.g., flumazenil) block the actions of other 
benzodiazepines, and can be used clinically as antidote for benzodiazepine toxicity. 
Ligands that are structurally unrelated to the benzodiazepines can also access the high-
affinity benzodiazepine site (e.g., zolpidem) to elicit similar responses. 
 
Extensive effort has gone into the delineation of benzodiazepine pharmacology using the 
representative ligand diazepam. It is now clear that diazepam, at low concentrations, 
indiscriminately modulates α1βγ2, α2βγ2, α3βγ2 and α5βγ2 GABAARs and is insensitive 
at α4βγ2 and α6βγ2 GABAARs. A conserved histidine residue found in the α1, α2, α3 and 
α5 subunits confers high-affinity diazepam sensitivity, whereas the homologous arginine 
in the α4 and α6 subunits renders these receptors diazepam insensitive. The histidine-to-
arginine mutation has been shown to selectively abolish diazepam activity at 
α1H101Rβ2γ2, α2H101Rβ2γ2, α3H126Rβ2γ2 and α5H105Rβ2γ2 recombinant 
receptors, and the reverse mutation produced diazepam-responsive α4R99Hβ2γ2 and 
α6R100Hβ2γ2 receptors [136-138]. Genetic studies have exploited this functional switch 
to engineer point-mutated mice bearing diazepam-insensitive α1, α2, α3 and/or α5 
subunits. Behavioural analysis of single point-mutated (only one type of diazepam-
insensitive α subunit) and triple point-mutated (only one type of diazepam-sensitive α 
subunit) mice in response to diazepam has helped define the functional role(s) of 
individual α subunits [90, 107, 139]. Taken together, these studies strongly suggest that 
sedation is primarily mediated by α1βγ2, anxiolysis by α2βγ2, myorelaxant by both α2- 
and α3βγ2, and amnesia by α5βγ2 GABAARs. In light of these findings, as well as the 
fact that the α1-preferring zolpidem displays mainly sedative hypnotic effects, there is a 
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surge of interest in the development of subtype-selective benzodiazepine site agonists 
with improved therapeutic profiles [140]. In particular, α2-selective modulators with 
anxioselectivity devoid of sedating property are highly sought after [141]. 
 
It is also worth mentioning that while the α4- and α6-containing receptors lack high 
sensitivity to diazepam, it does not mean that the high-affinity benzodiazepine site is 
absent altogether. Indeed, members of the same ligand class such as bretazenil and Ro 
15-4513 are able to bind to both diazepam-sensitive and insensitive GABAARs with high 
affinities [142]. Furthermore, the molecular determinants of these benzodiazepines are 
different from those of diazepam, as their functions are not diminished when the 
conserved histidine is mutated to arginine [138]. 
 
1.11.2.2.  Low-affinity benzodiazepine binding site(s) 
Many benzodiazepines also display additional low-affinity components at GABAARs. 
The binding site(s) responsible for these actions are poorly characterised, but evidence 
thus far suggests that the receptor responses mediated by these site(s) do not require the 
γ subunit, and may vary depending on the ligand, the concentration tested, and the type 
of subunits present [143]. The classical benzodiazepine diazepam, for instance, modulates 
α1β2γ2 GABAARs via two distinct mechanisms manifested as a biphasic potentiation 
with nanomolar and micromolar potencies [144]. The nanomolar component is mediated 
by the high-affinity benzodiazepine site, and can be selectively blocked by the antagonist 
flumazenil. The micromolar component, however, is flumazenil insensitive, and has been 
shown to be affected by mutations in the TMD where anaesthetics usually bind (section 
1.11.3). The physiological function of the low-affinity component is unclear, but has been 
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postulated to underlie diazepam’s anaesthetic property. Like diazepam, CGS 9895 
(Figure 1.9) has high- and low-affinity components at α1β3γ2 GABAARs [145]. At 
nanomolar concentrations, CGS 9895 acts as a neutralising modulator to block diazepam 
action. At micromolar concentrations, CGS 9896 potentiates GABAARs, an effect 
selectively mediated by a cluster of residues found on the α and β subunits (α1V211, 
α1S204, and β3Q64). Homology modelling has located this low-affinity benzodiazepine 
site on the extracellular α+β‒ interfaces, homologous to the classical benzodiazepine site 
(Figure 1.7). The therapeutical potential for subtype-selective ligands targeting this site 
is an area of interest [146-148]. 
 
1.11.3.   Anaesthetic binding sites in the TMD 
The transmembrane region of GABAARs harbours many solvent-accessible pockets 
which are the site of action for a range of structurally diverse chemicals including volatile 
anaesthetics (e.g., enflurane, isoflurane), general anaesthetics (e.g., etomidate, propofol), 
anticonvulsants (e.g., barbiturates, loreclezole), and sedative hypnotics (e.g., 
methaqualone) (Figure 1.9). These chemicals exhibit multiphasic activity at GABAARs, 
enhancing GABA-elicited current at clinical concentrations, directly activate receptors at 
high micromolar concentrations, and in some cases, act as open-channel blockers at even 
higher concentrations [149-151]. These binding sites are traditionally described in the 
context of their prototypical ligands. However, as more experimental evidence has 
become available to indicate that these sites are not unique to the prototype drugs, it is 
more appropriate to address them according to their locations.  
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1.11.3.1.  Transmembrane β+α‒ interfaces 
Two key approaches have hitherto contributed to the elucidation of the first class of 
anaesthetic binding sites, commonly referred to as the etomidate binding sites. First, using 
photoreactive analogues of etomidate ([3H]azietomidate and [3H]TDBzl-etomidate) 
which covalently label binding residues upon UV irradiation, photoaffinity labelling 
studies have jointly identified the βM286 (located in the M3 domain) and αM236 (located 
in the M1 domain) residues [152, 153]. Etomidate is able to inhibit the photolabelling of 
these residues in a concentration-dependent manner, further supporting etomidate’s 
interaction with both residues. Second, conventional and cysteine-substitution 
mutagenesis studies have also demonstrated that these methionine residues are important 
determinants of etomidate binding and function [154-156]. With the help of homology 
models based on various crystal structures of related receptors, βM286 and αM236 are 
predicted to be located at the β+α‒ interfaces in the TMD, just below the orthosteric 
binding sites (Figure 1.7). Other residues in the vicinity implicated in etomidate binding 
include βF289 (M3), βV290 (M3), αL232 (M1), αT237 (M1) and αI239 (M1) [153, 156]. 
 
1.11.3.2.  Transmembrane α+β‒ and γ+β‒ interfaces 
Another class of anaesthetic binding sites has recently been identified in α1β3γ2 
GABAARs using R-[
3H]mTFD-MPAB, a photoreactive barbiturate analogue [157]. These 
binding pockets are located at the α+β‒ and γ+β‒ interfaces, in homologous positions to 
the etomidate binding sites (Figure 1.7). Binding residues labelled by R-[3H]mTFD-
MPAB include αA291 (M3; equivalent to βM286), αY294 (M3) and γS301 (M3; 
equivalent to βM286) found on the principal faces of the respective subunits, whereas the 
βM227 (M1; equivalent to αL232) is found on the complementary face. 
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1.11.3.3.   Transmembrane β+β‒ interface 
Studies conducted in α1β3 GABAARs have also demonstrated that the photoreactive 
etomidate analogues and R-[3H]mTFD-MPAB which preferentially label β+ and β‒ 
residues respectively, also contact residues found on the opposite faces [153, 158]. 
[3H]Azietomidate and [3H]TDBzl-etomidate have been shown to photolabel βM227 on 
the complementary side, whereas R-[3H]mTFD-MPAB also photolabelled βM286 and 
βF289 located on the principal face. These findings suggest that a homologous cavity at 
the β+β‒ interface, which is absent in the αβγ subtypes is also accessible to these 
anaesthetics. 
 
1.11.3.4.  The promiscuity of anaesthetics binding 
While [3H]azietomidate and [3H]TDBzl-etomidate are highly selective for the β+α‒ 
interfaces, and R-[3H]mTFD-MPAB prefers the α+/γ+β‒ interfaces, the different classes 
of binding pockets are not exclusive to etomidate or barbiturates. Structurally dissimilar 
anaesthetics are able to compete with these photoreactive analogues to prevent residue 
photolabelling [157, 159]. Evidence from mutagenesis studies are in concordance with 
these findings. The substitution of methionine by tryptophan at residue 286 of the β 
subunit (βM286W) attenuates etomidate, propofol, volatile anaesthetics and 
methaqualone activity at GABAARs [160-162]. Moreover, the substituted cysteine 
accessibility method (SCAM) has also revealed that propofol protects the modification of 
α1M236C and β2M286C mutants by sulfhydryl-reactive reagent, indicating that propofol 
also contacts these residues [163, 164].  
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Thus, it appears that a structurally diverse set of chemicals including, but most likely not 
limited to the ligands investigated to date are able to access different number and classes 
of interfacial anaesthetic binding sites to exert their clinical effects. This heterogeneity is 
best exemplified by the convulsant S-mTFD-MPAB which selectively binds to the γ+β‒ 
interface to inhibit GABAARs [165], and the general anaesthetic propofol that binds non-
selectively to the β+α‒, α+β‒,γ+β‒ and β+β‒ interfaces to potentiate GABAARs [157, 
158]. More complexity is likely as other binding sites in the α+γ‒ transmembrane region, 
intrasubunit helical bundles and intracellular loop have also been suggested [143]. 
However, due to limitations associated with available experimental techniques, and the 
lack of crystal structures of anaesthetic-bound GABAARs, their existence remains to be 
confirmed. 
 
1.11.3.5  β2/3N265: critical sensitivity determinant, elusive role in binding 
The modulatory and agonistic actions of etomidate are more efficacious at β2/3- than β1-
containing GABAARs [149]. This functional difference is determined by a homologous 
residue at position 265 (M2 domain) of the β subunits (β1: serine; β2/3: asparagine). 
Mutational studies have demonstrated that etomidate sensitivity at β1-containing 
GABAARs is enhanced when the point mutation β1S265N is introduced, whereas the 
reverse mutation β2/3N265S negatively affects etomidate sensitivity [166]. This 
functional switch is shared with other β2/3-selective ligands such as loreclezole [167] and 
methaqualone [162]. When the βN265 residue is replaced with a methionine, the point 
mutation βN265M not only completely eliminates etomidate sensitivity, but also 
dramatically diminishes activity of propofol and enflurane [160, 168, 169]. Transgenic 
mice bearing the β2N265S or β3N265M point mutations are also resistant to distinct 
pharmacological actions of etomidate, propofol and pentobarbital [170-172].  
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Homology models built based on the recent β3 homomeric GABAAR as well as other 
related LGIC crystal structures have revealed that the N265 residue is located in the 
proximity of the β+α‒ etomidate/propofol binding sites [157, 158, 164]. However, none 
of the photoreactive anaesthetic analogues mentioned above has labelled this residue. 
Furthermore, the chemical modification of βN265C mutant by sulfhydryl-reactive probes 
was not protected by etomidate and propofol in SCAM studies, which argues against the 
direct interaction of anaesthetics with the residue [163, 164]. The ability of a single point 
mutation to have such drastic effects on different anaesthetics has led to the speculation 
that a common anaesthetic transduction pathway is impaired. Nevertheless, until more 
conclusive evidence becomes available, whether β2/3N265 mediates the binding and/or 
gating of anaesthetics remains tentative. 
 
1.11.4.   Neurosteroid binding sites in the TMD 
Endogenous steroids such as allopregnanolone (Figure 1.9) and their synthetic analogues 
have neuroactive effects such as anxiolysis, analgesia, sedation, anticonvulsant and 
anaesthesia mediated via GABAARs [173]. These neurosteroids potently enhance 
GABAAR function at low nanomolar concentrations, and activate GABAARs at 
submicromolar-to-micromolar concentrations. The mechanism(s) of action of 
neurosteroids are different from those of benzodiazepines and anaesthetics as 
demonstrated in mutational [160], photoaffinity labelling [174], and transgenic mice 
behavioural studies [171, 175]. Through the construction of chimera receptors followed 
by site-directed mutagenesis, an electrophysiological study has shown that αQ241 (M1), 
αN307 (M4) and αN410 (M4) residues are responsible for the potentiation by 
neurosteroids, whereas the agonistic action of neurosteroids is mediated by αT236 (M1) 
and βY284 (M3) residues [176]. Homology modelling located the modulatory site at the 
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M1-M4 interface within the α subunit, and the activation site occurs at the β+α‒ 
interfaces, between the M3 and M1 domains of the β and α subunits respectively (Figure 
1.7). These residues are conserved in all α and β subunits, which may explain the lack of 
subtype selectivity in neurosteroid activity [177].  
 
Naturally-occurring neurosteroids that block GABAARs (e.g., pregnenolone sulphate) 
also exist, but their physiological actions are not well defined. Evidence from binding and 
mutational studies suggest that inhibitory neurosteroids do not share the same sites with 
neurosteroids that augment GABAAR function. A residue found in the M2 domain of the 
α1 subunit (V256) which is located further down the channel pore has been implicated, 
but this putative inhibitory neurosteroid binding cavity is controversial and awaits further 
clarification [178]. All in all, neurosteroids appear to interact in a complex manner with 
at least three distinct transmembrane sites to potentiate, activate and inhibit GABAARs.  
 
1.11.5.   δ-selective ligands 
The δ subunit is exclusively found in extrasynaptic GABAARs with pronounced 
physiological significance and therapeutic relevance. However, the understanding of the 
properties of these receptors is hindered by their promiscuous assembly properties and 
also the scarcity of δ-selective pharmacological tools. The hypnotic drug THIP/gaboxadol 
directly activates αβδ with higher potency and efficacy (relative to GABA) than αβγ 
GABAARs [132]. However, THIP does not discriminate between αβ and αβδ receptors 
expressed in vitro [134], which may reflect the difficulty in achieving subunit selectivity 
by targeting the structurally conserved orthosteric binding sites. Unlike THIP, 4-chloro-
N-(2-thiophen-2-ylimidazo[1,2-a]pyridin-3-yl)benzamide (DS2; Figure 1.9) 
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predominantly acts as an efficacious positive modulator at α4/6βδ, has limited efficacy at 
αβγ and is inactive at αβ GABAARs [179]. Consistent with this δ-selective profile, the 
enhancement of tonic currents by DS2 in neurons is absent in δ-knockout mice [179, 180]. 
The location of the DS2 binding site(s) is not known, but the orthosteric and allosteric 
sites that etomidate, classical benzodiazepines, allopregnanolone and pentobarbital bind 
to have been excluded by binding and mutational studies [179]. Besides DS2, ketamine, 
AA29504 and JM-11-43-A also have δ-preferring activity, but there is limited evidence 
to confirm their selectivity [181-183]. 
  
1.12.   Natural products of plant origin and GABAARs 
GABAARs are the molecular target for a remarkable range of natural products of plant 
origin. Prominent examples of these plant-derived ligands include the GABAAR-defining 
antagonist bicuculline (from Dicentra cucullaria), the potent psychoactive agonist 
muscimol (from the intoxicating mushroom amanita muscaria), and the pore-blocking 
convulsant picrotoxin (from the Menispermaceae family) [184-186]. Interestingly, trace 
amounts of diazepam have also been detected in wheat and potato [187]. Given the long 
history of herbal medicine use in alleviating symptoms associated with CNS-related 
disorders implicating GABAARs such as anxiety and insomnia, the pharmacological 
active constituents of these herbs are of great therapeutical interest. Several emerging 
families of natural products-inspired GABAAR ligands are discussed below. 
 
1.12.1.  Flavonoids 
Flavonoids are found in great abundance in fruits, vegetables, herbs and beverages such 
as tea, coffee and red wine. There is tremendous structural diversity among flavonoids, 
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leading to division into eight classes, namely flavones, flavanones, flavonols, flavan-3-
ols, flavandiols, dihydroflavonols, isoflavones and anthocyanins (Figure 1.10A). These 
polyphenolic compounds are associated with health-promoting properties such as anti-
oxidant, anti-inflammatory, and anti-tumour [188]. In addition, lipophilic flavonoids are 
able to cross the blood-brain barrier to influence brain function [189, 190]. Among these 
neuroactive flavonoids, some modulate GABAARs with high affinity via the 
benzodiazepine site, and are anxioselective in mice [191, 192]. Subsequently, several 
synthetic efforts based on the flavonoid templates were undertaken, leading to the rapid 
expansion of a novel class of benzodiazepine site ligands [191, 193]. 
 
 
Figure 1.10. Natural products of plant origin that modulate GABAARs. (A) Major 
structural classes of flavonoids. (B) Synthetic flavones and flavan-3-ols with diverse 
pharmacology at GABAARs. (C) Valerenic acid isolated from Valeriana officinalis. (D) 
Honokiol and magnolol, bioactive constituents of Magnolia officinalis. 
38 
 
 
More recently, synthetic flavonoids with pharmacology clearly unrelated to the high-
affinity benzodiazepine site have been reported [194]. The anxiolytic flavan-3-ol 
derivative (2S,3R)-trans-3-acetoxy-4′-methoxyflavan (Fa131; Figure 1.10B) has a 
triphasic profile at GABAARs in vitro [195]. Mutations that impair anaesthetic sensitivity 
such as β2N265S and α1M236W reduce the modulatory action of Fa131, suggesting that 
the flavonoid may bind to the transmembrane anaesthetic sites [196]. A structurally-
related flavan-3-ol ester (2S,3S)-cis-3-acetoxy-4′-dimethoxyflavan (Fa173; Figure 
1.10B) is a neutralising modulator at GABAARs. While it lacks intrinsic activity, Fa173 
is able to selectively block the actions of Fa131, etomidate, loreclezole and the low-
affinity diazepam component [196]. Fa173 is the first antagonist with such profile known 
to date, and is expected to serve as a pharmacological tool in the study of the 
transmembrane anaesthetic sites, akin to flumazenil for the high-affinity benzodiazepine 
site. Flavone analogues such as 2′-methoxy-6-methylflavone (2′MeO6MF) and 3-
hydroxy-2′-methoxy-6-methylflavone (3-OH-2′MeO6MF; Figure 1.10B) also have anti-
anxiety effects in mice mediated via GABAARs in a flumazenil-insensitive manner [197, 
198]. These flavones exhibit complex pharmacology in vitro ranging from positive 
modulation, direct activation and no activity at distinct GABAAR subtypes. Besides that, 
a series of synthetic isoflavones have been demonstrated to produce flumazenil-
insensitive efficacious enhancement at GABAARs in vitro [199].  
 
Clearly, both natural and synthetic flavonoids are capable of influencing GABAAR 
function by directly binding to the high-affinity benzodiazepines site or the TMD where 
most anaesthetic sites reside. A flavonoid binding site on GABAARs has also been 
proposed, but its existence is yet to be systematically investigated. Nonetheless, the drug-
like physiochemical properties and anxiolytic-like effects of flavonoids make them a class 
of attractive lead compounds for drug development. Moreover, the diverse pharmacology 
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of flavonoids represents an opportunity to unravel the complex mechanisms of activation 
and modulation at GABAARs.   
 
1.12.2.  Valerenic acid 
Valerenic acid (Figure 1.10C), the major constituent of valerian root (Valeriana 
officinalis) is an allosteric modulator at GABAARs with anxiolytic and anticonvulsive 
effects. Functionally, valerenic acid positively modulates, activates and inhibits 
GABAARs across its effective concentration range (1–300 µM) [200]. Furthermore, 
valerenic acid displays an etomidate-like selectivity profile, with more efficacious 
modulation recorded at β2/3- than β1-containing GABAARs. Consistent with this finding, 
mutations at β265 residue (β1S265N, β2N265S and β3N265M) were found to affect the 
activity of valerenic acid in vitro and in vivo [200, 201]. With the use of homology 
modelling, molecular docking, pharmacophore and site-directed mutagenesis, Luger et 
al. (2015) identified residues critical for the activity of valerenic acid on the β3 subunit, 
some of which correspond to the established etomidate/propofol binding residues, 
suggesting that valerenic acid also binds to the cavities in the transmembrane β+α‒ 
interfaces [202]. However, as other homologous interfacial sites were not investigated, 
the possibility of other binding pockets cannot be excluded. There is also interest in the 
clinical application of valerenic acid as an anxiolytic or anticonvulsant, with several lead 
optimisation attempts made to improve its pharmacokinetic and pharmacodynamic 
parameters [203, 204]. 
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1.12.3.  Honokiol and magnolol 
The bark of Magnolia officinalis is used in traditional Chinese and Japanese medicine to 
treat insomnia and anxiety. Honokiol and magnolol (Figure 1.10D) are the 
pharmacologically active constituents with a variety of enzymes and receptors proposed 
to be the site of action [205]. GABAARs are thought to be one of the most plausible 
targets, on the basis of their remarkably similar properties to the benzodiazepines such as 
sedative, anxiolytic, muscle relaxant, anticonvulsant and anaesthetic. Animal behavioural 
studies appear to support the CNS actions of honokiol and magnolol being mediated via 
the high-affinity benzodiazepine site, as these effects are sensitive to flumazenil 
antagonism [206-209]. Electrophysiological studies show that both honokiol and 
magnolol are able to potentiate native GABAARs found in rat neurons [210, 211]. These 
compounds also positively modulates heterologously expressed αβ, αβγ and αβδ 
GABAARs with no subtype selectivity, thus argues against the α+γ‒ benzodiazepine site 
as the site of action [211]. The reason for the discrepancy between in vitro and in vivo 
studies is not clear. Furthermore, mutations in the transmembrane M2, M3 and M3 
domains which impair the action of several different classes of anaesthetic agents have 
insignificant effect on the action of honokiol and magnolol [211]. The binding site(s) for 
these natural products on GABAARs remain obscure at this stage, but has not hindered 
the search for structural analogues with improved potency and efficacy. Extensive 
structure-activity studies have led to a vast array of honokiol and magnolol derivatives, 
with some of them possessing subtype selectivity and extraordinary efficacy [212-214].  
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1.13. Thesis rationale  
The focus of this thesis revolves around the action of 2′MeO6MF, a synthetic flavonoid, 
and kavain, a naturally occurring kavalactone at GABAARs.  
 
1.13.1.  2′MeO6MF 
The synthetic flavonoid 2′MeO6MF is an allosteric ligand with complex pharmacology 
at GABAARs [197]. The selective agonistic action of 2′MeO6MF at α2β2/3γ2L 
GABAARs is thought to be the reason for its in vivo anxioselectivity. The mechanism(s) 
behind its unique pharmacological profile, however, is not known. Efforts to identify the 
specific binding region(s) of 2′MeO6MF have been futile as considerable variability of 
its action is observed within our laboratory and between different laboratories. We 
hypothesise that mixed receptor populations, a common problem in the heterologous 
expression of multimeric receptors, is the culprit. The first project aims to address the 
variability of 2′MeO6MF activity at α2β3γ2L GABAARs by systematically expressing all 
possible receptor combinations in Xenopus oocytes using α2, β3 and γ2L subunits, and 
test 2′MeO6MF function on individual receptor combination using electrophysiological 
methods. It is expected that data generated by this study will provide hints to explain the 
variability observed in 2′MeO6MF action. 
 
1.13.2.  Kavalactones 
The intoxicating pepper plant kava has been used for millennia to treat insomnia and 
anxiety by the Pacific Islanders. Kava’s bioactive constituents, commonly known as 
kavalactones (Figure 4.1) are in the limelight due to their efficacy in reducing anxiety in 
several small-scale clinical trials [215, 216]. There is also an ongoing phase III clinical 
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trial attempting to establish the efficacy and safety of kavalactones in treating generalised 
anxiety disorder in a larger and longer study [217]. Despite a growing body of clinical 
evidence in support of kavalactones’ medicinal values, the basic pharmacology of 
kavalactones remains enigmatic. GABAARs have been proposed due to the frequent 
association of benzodiazepines with anti-anxiety effects. However, only a number of 
binding studies have investigated the interaction of kavalactones with GABAARs to date, 
and the evidence is inconsistent due to the use of kava extracts containing an assortment 
of chemicals. As such, the second project aims to characterise the function of individual 
kavalactones at various physiologically relevant human GABAAR subtypes expressed in 
Xenopus oocytes. Besides that, it is also our aim to elucidate the mechanism of action of 
kavalactones with the use of pharmacological tools that target distinct allosteric binding 
sites at GABAARs. Through this study, we hope to obtain more conclusive proof which 
will establish the direct interaction of kavalactones with GABAARs. 
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Chapter 2 
Materials and Methods 
______________________________________ 
 
2.1. Introduction 
The expression of recombinant ion channels in heterologous systems such as mammalian 
cell lines and Xenopus laevis frog oocytes is a critical approach in the study of ligand-
gated ion channels. In conjunction with molecular biological and electrophysiological 
recording techniques, the structure-function relationship of a receptor of interest can be 
explored under controlled conditions. Defined mutations could also be introduced in these 
receptors to facilitate the elucidation of the binding site of a ligand of interest.  
 
For the purpose of this thesis, Xenopus oocytes were used to study GABAARs for 
numerous reasons [1, 2]. First, their large sizes and robust nature allow mRNA 
microinjection and electrophysiological recording to be conducted relatively easily. 
Second, by varying the ratio of the mRNA encoding for different subunits, the subunit 
composition of GABAARs expressed could be controlled (assuming that all subunits 
express equally well). Third, the lack of endogenous GABAARs in Xenopus oocytes 
allows the investigation of the function of a single, defined receptor subtype of interest 
without the contamination from native receptors. Lastly, as Xenopus oocytes translate 
exogenous mRNA very efficiently, the amount of mRNA injected could be adjusted to 
achieve desirable expression levels.  
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This chapter details the materials and methods used throughout this thesis. A 
comprehensive list of chemicals, reagents, media, buffers and equipment is provided. The 
general methodology involving molecular biological techniques, preparation of Xenopus 
oocytes, two-electrode voltage clamp electrophysiology recording and data analysis is 
also described in detail.  
 
2.2. Safety, regulations and ethics 
All experiments conducted followed the general guidelines stated in the Safety Handbook 
of Faculty of Pharmacy, University of Sydney. Quarantine Awareness training (endorsed 
by the Department of Agriculture, Australian Government) and Quarantine Approved 
Premises accreditation (endorsed by the Australian Quarantine and Inspection Service, 
Australian Government) were obtained prior to the commencement of any procedures 
which required handling of Xenopus laevis frogs as well as their oocytes. All the 
procedures involved in the use of Xenopus laevis frogs for the purpose of this thesis were 
approved by the Animal Ethics Committee of the University of Sydney (Reference 
number: 2013/5915). 
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2.3. Materials 
2.3.1. Chemicals and reagents 
 
Table 2.1. General chemicals and reagents. 
Chemicals/reagents Source 
Ambion® Nuclease-free water Thermo Fisher Scientific (Scoresby, VIC, Australia) 
Ampicillin sodium salt Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
Ethanol (for molecular biology) Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
Gentamicin solution (50 mg/mL) Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
Glycerol (for molecular biology) Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
Mineral oil (for molecular biology) Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
SBYR® Safe DNA Gel Stain Thermo Fisher Scientific (Scoresby, VIC, Australia) 
Sodium hydroxide (NaOH) pellets  Asia Pacific Specialty Chemical Ltd 
Tetracycline HCl Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
UltraPure™ Agarose Thermo Fisher Scientific (Scoresby, VIC, Australia) 
1 kb DNA ladder Genesearch Pty Ltd (Arundel, QLD, Australia) 
 
Table 2.2. Chemicals used in electrophysiological studies. 
Chemicals Source 
Allopregnanolone Tocris Bioscience (Bristol, UK) 
Diazepam Apin Chemicals LTD (Abingdon, Oxon, UK) 
DMSO Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
DS2 Tocris Bioscience (Bristol, UK) 
Etomidate HCl 
Synthesised by Dr. Raja Viswas (Faculty of Pharmacy, University 
of Sydney, NSW, Australia) following protocols described in 
Janssen et al. [3] and Janssen et al. [4] 
Flumazenil Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
GABA Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
propofol Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
DL-kavain Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
2′MeO6MF 
Synthesised by Dr. Raja Viswas (Faculty of Pharmacy, University 
of Sydney, NSW, Australia) as described in Karim et al. [5] 
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2.3.2. Bacterial growth media 
The following media were prepared as described and stored at room temperature. 
Table 2.3. Media used for bacterial growth. 
 LB Agar (Lennox L Agar) Terrific Broth 
Ingredients 
(amount/L 
of media) 
10 g SELECT Peptone 140 11.8 g SELECT Peptone 140  
5 g SELECT Yeast Extract 23.6 g yeast extract 
5 g NaCl  9.4 g dipotassium hydrogen phosphate 
12 g SELECT Agar 2.2 g potassium dihydrogen phosphate  
 4 mL of glycerol (carbon source) 
Preparation 
35 g powder/1 L deionised water; 
autoclaved at 121 °C for 1 hour 
47.6 g powder/1 L deionised water; 
autoclaved at 121 °C for 1 hour 
Source 
Thermo Fisher Scientific 
(Scoresby, VIC, Australia) 
Thermo Fisher Scientific  
(Scoresby, VIC, Australia) 
 
2.3.3. Buffers 
The following buffers were used throughout this thesis. Buffers with proprietary 
ingredients were not included. 
Table 2.4. Buffers used for molecular biology purposes. 
Buffers Ingredients Source 
CutSmart® Buffer 
(1×) 
50 mM  potassium acetate,  
Genesearch Pty Ltd 
(Arundel, QLD, Australia) 
20 mM tris-acetate,  
10 mM magnesium acetate  
100 µg/mL BSA  
(pH 7.9 at 25 °C). 
Gel Loading Buffer 
II 
95 % Formamide 
Thermo Fisher Scientific 
(Scoresby, VIC, Australia) 
18 mM EDTA 
0.025 % SDS 
0.025 % Xylene Cyanol 
0.025 % Bromophenol Blue 
NTP/CAP (2×), 
mMessage 
mMachine® T7 
Transcription Kit 
15 mM ATP 
Thermo Fisher Scientific 
(Scoresby, VIC, Australia) 
15 mM CTP 
15 mM UTP 
2 mM GTP 
8 mM cap analog 
TAE Buffer (10×) 
40 mM Tris-acetate Sigma-Aldrich Pty Ltd 
(Castle Hill, NSW, 
Australia) 
5.7 % (v/v) glacial acetic acid 
0.01 M EDTA (pH 8.0) 
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The recipes of buffers used in the defolliculation, storage and electrophysiological 
recording of Xenopus oocytes are summarised in Table 2.5. All buffer ingredients were 
purchased from Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia). 
 
Table 2.5. Buffers used in the handling of Xenopus oocytes. 
Ingredients  
Buffers (1×) 
OR2* ND96 (storage)* 
ND96 
(electrophysiology) † 
NaCl 82.5 mM 96 mM 96 mM 
KCl 2 mM 2 mM 2 mM 
MgCl2 1 mM 1 mM 1 mM 
CaCl2 – 1.8 mM 1.8 mM 
HEPES – – 5 mM 
HEPES hemisodium 5 mM 5 mM – 
Theophylline – 0.5 mM – 
Na pyruvate – 2.5 mM – 
 
* Filtered with the Stericup® Filter Units (Merck Millipore, Bayswater, VIC, Australia). 
† pH was adjusted to 7.4 with NaOH using a benchtop pH meter. 
 
2.3.4. Enzymes, competent cells and kits 
The following enzymes, competent cells and kits were used for the purpose of this 
thesis.  
Table 2.6. Enzymes, competent cells and kits. 
 
Source 
Enzymes 
Collagenase A 
Boehringer Mannheim Australia 
Pty Ltd (North Ryde, NSW, 
Australia) 
Restriction enzymes  
(HpaI, NheI-HF®, NotI-HF®, SmaI) 
Genesearch Pty Ltd (Arundel, 
QLD, Australia) 
Competent 
E. coli cell 
lines 
NEB 10-beta 
Genesearch Pty Ltd (Arundel, 
QLD, Australia) 
TOP10/P3 
Thermo Fisher Scientific 
(Scoresby, VIC, Australia) 
Kits 
mMessage mMachine® T7 
Transcription 
Thermo Fisher Scientific 
(Scoresby, VIC, Australia) 
61 
 
 
QIAprep® Spin Miniprep 
Qiagen (Chadstone, VIC, 
Australia) 
QIAquick® Nucleotide Removal 
Qiagen (Chadstone, VIC, 
Australia) 
QIAquick® PCR Purification 
Qiagen (Chadstone, VIC, 
Australia) 
QuikChange II Site-Directed 
Mutagenesis 
Agilent Technologies Australia 
(Mulgrave, VIC, Australia) 
 
 
2.3.5. General apparatus and equipment 
 
Table 2.7. General apparatus and equipment. 
Equipment Source 
Autoclave Atherton (Thornbury, VIC, Australia) 
Block heater (Stuart) Bibby Scientific Ltd (Staffordshire, OSA, UK) 
Centrifuge (Eppendorf, 5417R) 
Thermo Fisher Scientific (Scoresby, VIC, 
Australia) 
Drummond Scientific glass capillaries  
(OD: 1.4 mm, ID: 0.53 mm, l: 3.5′′)* 
Thermo Fisher Scientific (Scoresby, VIC, 
Australia) 
GeneClamp 500B Amplifier ADInstruments, Sydney, NSW, Australia 
Harvard Apparatus glass capillaries  
(OD: 1.2 mm, ID: 0.94 mm, l: 100 mm)* 
SDR Scientific (Chatswood, NSW, Australia) 
Microprocessor-controlled vertical 
pipette puller (PUL-100) 
World Precision Instruments, Inc. (Sarasota, 
FL, USA) 
Microscopes (SZ-61) Olympus (North Ryde, NSW, Australia) 
NanoDrop 1000 Spectrophotometer 
Thermo Fisher Scientific (Scoresby, VIC, 
Australia) 
Nanoliter 2000 microinjection system Drummond Scientific (Broomali, PA, USA) 
PowerLab 2/25 ADInstruments, Sydney, NSW, Australia 
PowerPack™ Basic Power Supply 
Bio-Rad Laboratories Pty Ltd (Gladesville, 
NSW, Australia) 
Shaking incubators  Labec (Marrickville, NSW, Australia) 
Single-stage glass microelectrode puller 
(PP-830) 
Narishige (Tokyo, Japan) 
Stericup® Filter Units  Merck Millipore (Bayswater, VIC, Australia) 
Thermal Cycler (T100™) 
Bio-Rad Laboratories Pty Ltd (Gladesville, 
NSW, Australia) 
Warner OC-725C Oocyte Clamp   Warner Instrument Corp, Hamden, CT, USA 
* OD: outside diameter, ID: inside diameter, l = length 
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2.3.6. GABAAR subunits 
A total of 10 different GABAAR subunits (α1–5, β1–3, γ2L and δ) were used in this 
thesis, and their origins, subcloned plasmid vectors, sources and the chapters they 
appeared in are summarised in Table 2.8.  
 
Table 2.8. A summary of all GABAAR subunits used in this study. 
GABAAR 
subunit 
Origin 
UniProt 
Entry 
Plasmid vector 
Restriction 
enzyme 
Source Chapter 
α1 Human P14867 pCDM8 NotI-HF † 4 
α2 Human Q8TBI4 pCMV6-XL5 SmaI ‡ 3 
α4 Human P48169-1 pCDNA1/Amp HpaI § 4 
α5 Human P31644-1 pCDNA3 NotI-HF § 4 
β1 Human* P18505-1 pCDM8 HpaI § 4 
β2 Human P47870-1 pCDM8 NotI † 4 
β3 Human P28472-1 pGEMHE NheI-HF § 3, 4 
γ2L Human P18507-2 pCDM8 NotI-HF † 3, 4 
δ Human O14764-1 pCDNA1/Amp HpaI § 4 
* The β1 subunit is of the human origin, but has a bovine signal sequence. 
† Gift from Dr. Paul Whiting (Merck Sharpe and Dohme, Harlow, UK). 
‡ Purchased from OriGene Technologies, Rockville, MD, USA. 
§ Gift from Professor Bjarke Ebert (H. Lundbeck A/S, Alby, Denmark). 
 
2.3.7. Oligonucleotide primers 
Oligonucleotide primers used in site-directed mutagenesis reactions were synthesised by 
Sigma-Aldrich Pty Ltd (Castle Hill, NSW, Australia) and Thermo Fisher Scientific 
(Scoresby, VIC, Australia). The sequences and other information about specific primers 
are provided in the relevant sections. 
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2.4. Methods 
2.4.1. Molecular biology 
2.4.1.1. Transformation of plasmid DNA into E. coli 
Desired wild-type or mutant plasmid DNAs were transformed into appropriate competent 
E. coli cell lines. TOP10/P3 cells were used for subunits subcloned into the pCDM8 
vector (α1, β1, β2 and γ2L subunits), whereas the NEB 10-beta competent cells were used 
for other subunits (Table 2.8). A tube containing 50 µL of competent cells was thawed 
on ice before the addition of 1–5 µL containing 100–300 ng of plasmid DNA. After 30 
minutes of incubation on ice, the cell mixture was heat-shocked at 42 ºC on a block heater 
for 45 seconds, and then placed on ice for another 10 minutes. Following that, 500 µL of 
Terrific Broth was added to the cell mixture, and the tube was then incubated at 37 ºC in 
a shaking incubator (220 rpm) for 60 minutes. The cell mixture was mixed thoroughly 
after incubation before they were spread on LB Agar plates containing the appropriate 
antibiotics (TOP10/P3: 100 µg/mL ampicillin + 10 µg/mL tetracycline; NEB 10-beta: 
100 µg/mL ampicillin only). The plates were air dried, inverted and incubated at 37 ºC 
overnight (12–18 hours, depending on growth rate). 
 
2.4.1.2. Growth of E. coli cultures 
For transformed NEB 10-beta cells, a single bacterial colony was picked from the LB 
Agar plate using a pipette tip which was then dropped into a 50 mL Falcon tube containing 
5 mL Terrific Broth supplemented with 100 µg/mL ampicillin. The inoculated media was 
then incubated at 37 ºC in a shaking incubator (220 rpm) overnight (≥ 16 hours, depending 
on growth rate). For transformed TOP10/P3 cells, due to the relatively low yields of 
plasmid DNA, inoculated Terrific Broth was incubated at 37 ºC with shaking at 220 rpm 
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for 1–2 hours to initiate growth before the addition of antibiotics (100 µg/mL ampicillin 
+ 10 µg/mL tetracycline). Incubation continued at 37 ºC with shaking at 220 rpm 
overnight (≥ 16 hours). 
 
2.4.1.3. Bacterial glycerol stocks 
For long-term storage of plasmids, bacterial glycerol stocks were created and stored at -
80 ºC. Glycerol is a cryoprotectant that helps with cell viability by protecting bacteria 
from freezing damage. Bacterial glycerol stocks were created by mixing 500 µL of 
overnight cultures with 500 µL of 50 % glycerol in a 2 mL screw top tube, snap-frozen 
in a dry ice and ethanol bath, and then stored at -80 ºC. 
 
2.4.1.4. Purification, quality assessment and quantification of plasmid DNA 
Plasmid DNA was isolated and purified using the QIAprep Spin Miniprep Kit following 
the manufacturer’s instructions. Briefly, bacteria in overnight cultures were pelleted by 
centrifugation at 10, 000 rpm for 3 minutes using the Eppendorf Centrifuge at room 
temperature. Pelleted bacteria were resuspended in 250 µL of Buffer P1 (supplemented 
with RNase A to hydrolyse RNA, and thus prevent co-purification of RNA with plasmid 
DNA) before being lysed by the addition of 250 µL of Buffer P2 (contains NaOH and 
SDS). SDS helps cell lysis by solubilising phospholipid and proteins of cell membrane, 
whereas the strong base NaOH denatures chromosal and plasmid DNAs, as well as 
proteins released from the bacteria. 350 µL of Buffer N3 (contains guanidinium chloride 
and acetic acid; pH 4.3) was then added to neutralise the alkaline conditions of the lysate, 
allowing the macromolecules to renature. The high salt concentrations, however, causes 
the larger chromosal DNA, proteins, debris and SDS to aggregate and precipitate out of 
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the solution, while the small plasmid DNA renatures properly and stays soluble in the 
solution. The precipitant was pelleted by centrifugation at 14, 000 rpm for 10 minutes, 
and the clear supernatant containing the plasmid DNA was applied to the spin column 
where selective adsorption of the plasmids occur at the silica-gel membrane in high-salt 
conditions. 750 µL of Buffer PE (contains ethanol) was then added to the spin column to 
remove salts, and the column was spun twice to ensure no residual washing buffer 
remained. 30–50 µL of Buffer EB (10 mM Tris.Cl, pH 8.5) was used to elute the plasmid 
DNA from the spin column. 
 
The presence of purified plasmid DNAs was confirmed using agarose gel electrophoresis. 
Agarose gels of 1 % (w/v) were made by dissolving 0.50 g UltraPure™ Agarose powder 
in 50 mL of 1× TAE buffer with 5 µL of SBYR® Safe DNA Gel Stain. DNA samples 
were mixed at a 1:1 ratio with Gel Loading Buffer II. A 1 kb DNA ladder was run 
alongside the DNA samples for each gel. Electrophoresis was performed at 100 V and 
400 mA using the PowerPac™ Basic Power Supply for 30–45 minutes. DNA bands were 
visualised using the Gel Doc™ EZ System and the Image Lab™ software. Clear and 
defined bands on the gel indicate the presence of high quality plasmid DNA (Figure 
2.1A). The quality and quantity of the plasmid DNA were further analysed using the 
NanoDrop 1000 Spectrophotometer. The spectrophotometer measures the concentration 
of DNA (ng/µL) in a sample, besides providing information on sample purity in the form 
of ratio of sample absorbance at a wavelength of 260 nm and 280 nm (260/280), as well 
as 260/230 (Figure 2.1B). DNA samples with a ratio of ~1.8 for 260/280 and 1.8–2.2 for 
260/230 are generally accepted as “pure”.    
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Figure 2.1. The quality assessment and concentration measurement of purified 
plasmid DNA. (A) An example of agarose gel electrophoresis of purified DNA from E. 
coli. Lane 1: 1 kb DNA ladder; 2: purified plasmid DNA of GABAAR β3 subunit; 3: 
linearised plasmid DNA of GABAAR β3 subunit. The two bands in lane 2 correspond to 
the two topologically-different forms of circular plasmid DNAs. The supercoiled form 
travels faster and is found further down the gel compared to the nicked, relaxed circle 
form. (B) The quantification of plasmid DNA samples using the NanoDrop 1000 
Spectrophotometer. The sample measured contained plasmid DNA of GABAAR α2 
subunit. The concentration of DNA measured was 154.8 ng/µL and the sample purity was 
confirmed by the 260/280 and 260/230 ratios (inset) within the recommended range (see 
section 2.4.1.5).  
 
2.4.1.5. Verification of purified plasmid DNA identities 
The identities of all wild-type and mutated plasmid DNAs were verified by sequencing 
the entire gene of interest using appropriate primers. Samples containing 600–1500 ng 
purified DNA and 0.8 pmol/µL primers were made up to 12 µL with nuclease-free water, 
and then sent to Sanger Sequencing, Australian Genome Research Facility Ltd 
(Westmead, NSW, Australia) for sequencing. Raw traces (.ab1 files) were read using the 
CodonCode Aligner software (version 4.0.4 demo, CodonCode Corporation) and 
translated to amino acid sequences using the online ExPASy translate tool. The amino 
acid sequences of DNA samples were then compared against the corresponding protein 
sequences found in the UniProt database using the online Clustal Omega multiple 
sequence alignment program.  
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2.4.1.6. Linearisation of plasmid DNA 
Circular plasmid DNA was linearised using restriction enzymes to allow for the 
production of mRNA transcripts derived from the insert GABAAR subunit sequences only 
(without the contamination from vector sequences). Briefly, 1–3 µg of plasmid DNA was 
treated with 1–2 U of restriction enzymes (Table 2.8) and 1× CutSmart® Buffer in a final 
reaction volume of 50 µL. All reactions were carried out on a Thermal Cycler at 37 ºC 
for 2 hours, except for when SmaI enzyme was used (25 ºC). Linearised DNA was 
purified using the QIAquick® Nucleotide Removal Kit. Briefly, 5 volumes of Buffer PNI 
were added to 1 volume of the reaction mixture, transferred to a spin column which was 
then centrifuged at 6000 rpm for 1 minute. The flow-through was discarded, and the spin 
column was washed with 750 µL of Buffer PE, followed by centrifugation at 6000 rpm 
for 1 minute. The flow-through was discarded, and the spin column was centrifuged at 
13,000 rpm for another minute to remove any residual buffer. The linearised DNA was 
then eluted from the column to a clean 1.5 mL Eppendorf tube using 30–50 µL of Buffer 
EB. To ensure complete cleavage of the circular DNA, samples were analysed using 
agarose gel electrophoresis. A clear, defined band indicates that all circular DNA has been 
cut (Figure 2.1A). 
 
2.4.1.7. Synthesis, quality assessment and quantification of mRNA 
The mMessage mMachine® T7 Transcription Kit was used for the synthesis of capped 
RNA of a GABAAR subunit of interest. The term ‘mRNA’ was used instead of ‘capped 
RNA’ in this thesis. The components and the required amounts for a transcription reaction 
is summarised in Table 2.9. A full reaction was used to make wild-type receptor subunit 
mRNA, whereas a half reaction was used for mutant mRNA. 
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          Table 2.9. mRNA transcription setup. 
Component 
Amount 
Full reaction Half reaction 
2× NTP/CAP 10 µL 5 µL 
10× Reaction Buffer 2 µL 1 µL 
Linearised DNA (50–200 ng/µL) 6 µL 3 µL 
T7 enzyme mix 2 µL 1 µL 
Total reaction volume 20 µL 10 µL 
 
The transcription reaction was carried out on a Thermal Cycler at 37 ºC for at least 3 
hours to ensure high yields. At the end of the reaction, 1 µL TURBO DNase was added 
to the mixture, followed by 15 minutes of incubation at 37 ºC to remove the template 
DNA. The lithium chloride (LiCl) precipitation method was used to recover and purify 
mRNA. First, the reaction mixture was mixed thoroughly with 30 µL of LiCl Precipitation 
Solution, and was stored at -20 ºC overnight. Then, the mRNA was pelleted by 
centrifugation (14, 000 rpm) at 4 ºC for 15 minutes. The supernatant containing 
unincorporated nucleotides and proteins was removed, and the mRNA pellet was washed 
with 500 µL of 70 % ethanol. The mixture was then re-centrifuged (4 ºC; 14, 000 rpm; 
15 minutes), and the ethanol was removed. The ethanol wash step was repeated twice to 
maximise removal of unincorporated nucleotides. The mRNA pellet was resuspended in 
10–20 µL of nuclease-free water when all residual ethanol had been removed. 
 
The quality of mRNA was assessed using agarose gel electrophoresis as described in 
section 2.4.1.5, except the mRNA sample (+ Gel Loading Buffer II) was denatured at 94 
ºC on a block heater before gel loading. Intact mRNA samples appeared as clear, distinct 
bands on the gel, whereas degraded samples produced a smear. The quantification of 
purified mRNA samples involved the use of NanoDrop 2000 Spectrophotometer (see 
section 2.4.1.5). The amount of mRNA in a sample is measured in ng/µL, and the purity 
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is indicated with 260/280 and 260/230 ratios. A 260/280 ratio of ~2.0 and a 260/230 ratio 
of 2.0–2.2 are generally accepted as pure. 
 
Figure 2.2. The quality assessment and concentration measurement of synthesised 
mRNA. (A) An example of agarose gel electrophoresis of intact mRNA samples. Lane 
1: 1 kb DNA ladder; 2 and 3: GABAAR β3 subunit mRNAs. (B) An example of agarose 
gel electrophoresis of degraded mRNA samples which appeared as smeared bands in lane 
2 and 3. (C) The quantification of mRNAs using the NanoDrop 1000 Spectrophotometer. 
The sample measured contained mRNA of GABAAR α1 subunit. The concentration of 
mRNA measured was 1085.3 ng/µL and the sample purity was confirmed by the 260/280 
and 260/230 ratios (inset) within the recommended range (see section 2.4.1.7). 
 
2.4.1.8. Site-directed mutagenesis 
Single amino acid substitution mutations were introduced to various GABAAR subunits 
of interest using the QuikChange II Site-Directed Mutagenesis Kit. To create a desired 
mutation, a forward primer containing the altered sequence positioned in the middle of 
approximately 30 wild-type nucleotide bases was designed. A reverse primer which has 
a reverse complement sequence to that of the forward primer was also designed to cover 
the opposite DNA strand. The forward and reverse primers sequences used to create 
specific mutations are provided in relevant chapters.  
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The mutagenesis reaction was carried out on a Thermal Cycler, and involves three major 
steps: denaturation at 95 ºC to separate plasmid DNAs into single strands; annealing at 
55 ºC to allow for the primers to attach to the single DNA strands; and primer extension 
by DNA polymerase at 68 ºC. The reaction mixtures were assembled as described in 
Table 2.10, and cycled using parameters detailed in Table 2.11. Following temperature 
cycling, 1 µL of Dpn I restriction enzyme (10 U/µL) was added to each reaction mixture, 
further incubated at 37 ºC for 1 hour to digest the parental (non-mutated) plasmid DNAs. 
 
The amplified mutant plasmid DNA was purified using the QIAquick® PCR Purification 
Kit. Briefly, 5 volumes of Buffer PB were added to 1 volume of the reaction mixture, 
transferred to a spin column which was then centrifuged at 13, 000 rpm for 1 minute. The 
flow-through was discarded, and the spin column was washed with 750 µL of Buffer PE, 
followed by centrifugation at 13, 000 rpm for 1 minute. The flow-through was discarded, 
and the spin column was centrifuged at 13,000 rpm for another minute to remove any 
residual buffer. The mutant DNA was then eluted from the column to a clean 1.5 mL 
Eppendorf tube using 30 µL of Buffer EB. The purified mutant DNA was then 
transformed into E. coli (section 2.4.1.1), and steps 2.4.1.2–2.4.1.7 were repeated to 
obtain mutant subunit mRNA. 
 
Table 2.10. Site-directed mutagenesis reaction setup. 
Component Amount 
10× Reaction Buffer 5 µL 
Plasmid DNA (5–50 ng) X µL 
Forward primer (125 ng) X µL 
Reverse primer (125 ng) X µL 
dNTP mix 1 µL 
Nuclease-free water to 50 µL 
PfuUltra HF DNA polymerase (2.5 U/µL) 1 µL 
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Table 2.11. Cycling parameters for the site-directed mutagenesis reactions. 
Segment Cycles Temperature Time Step 
1 1 95 ºC 30 seconds Denaturation 
2 16 
95 ºC 30 seconds Denaturation 
55 ºC 1 minute Annealing 
68 ºC 1 minute/kb of plasmid length Extension 
 
2.4.2. Xenopus oocytes: harvesting, defolliculation and microinjection 
Surgical harvesting 
Before surgery, mature female Xenopus laevis frogs were anaesthetised with 0.17 % 
tricaine (buffered with 0.06 % sodium bicarbonate) for 12 minutes. The loss of righting 
reflex was confirmed before transferring on to ice where surgeries were performed. A 
small (1–2 cm) abdominal incision was made through both the skin and muscle layer with 
surgical knives. Ovary lobes were removed with a pair of forceps, and kept in OR2 buffer.  
The skin and muscle layers were sutured separately, and frogs were allowed to recover 
for six months before they were reselected for surgeries. A total of five recoverable 
surgeries were allowed on each frog, before a terminal surgery was performed, in which 
a lethal dose of tricaine (0.5 %) was used.  
 
Defolliculation 
Removed ovary lobes were divided into small sections with the use of scissors, which 
were then treated with 2 mg/mL Collagenase A (dissolved in OR2 buffer) in a shaking 
incubator for an hour to defolliculate the oocytes. The concentration of Collagenase A 
was then diluted to 1 mg/mL, and the cells were checked at 15-minute intervals until 
defolliculation was complete. The oocytes were then rinsed in OR2 followed by ND96 
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storage solutions to remove Collagenase A and dead cells. Healthy-looking stage V–VI 
oocytes were isolated and kept in ND96 storage buffer at 18 °C until ready for injection.  
 
Microinjection 
To create injection micropipettes, Drummond Scientific borosilicate glass capillaries 
were pulled apart using a microprocessor-controlled vertical pipette puller with two 
pulling stages (Stage 1: Heat = 560, Pull = 0, Trip = 130, Delay = 40; Stage 2: Heat = 
580, Pull = 0, Trip = 80, Delay = 40), and then blunted with a spatula to produce a tip 
with an approximate diameter of 10–20 µm. The micropipettes were filled with mineral 
oil using a syringe, ensuring no air bubbles were introduced in the process. Filled 
micropipettes were then placed into the injector of the Nanoliter 2000 microinjection 
system. Various combinations of GABAAR subunit mRNAs were mixed to different 
ratios and diluted accordingly to a desired concentration as stated in relevant sections. 
The mRNA mixture was taken up into the micropipette, then injected into the cytoplasm 
of oocytes (50 nL/injection) using the Nanoliter 2000 microinjection system. Injected 
oocytes were stored in ND96 storage solution supplemented with 50 µg/mL gentamycin 
and 50 µg/mL tetracycline, and incubated with continuous shaking at 18 °C. 
 
 
2.4.3. Two-electrode voltage-clamp technique 
Two-electrode voltage clamp recordings were performed on oocytes 2–4 days post-
injection at room temperature (20–25 °C) using a GeneClamp 500B amplifier or a Warner 
OC-725C Oocyte Clamp.  All experiments were conducted at a holding potential of –60 
mV unless otherwise stated, and data were acquired with a PowerLab 2/25, and LabChart 
(version 5.0.2) software. The recording microelectrodes (0.2–1.1 MΩ) were generated 
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from Harvard Apparatus glass capillaries using the single stage microelectrode puller 
(heater level = 68) and were filled with 3 M KCl solution. The perfusion system was built 
using a series of polycarbonate, high-density polyethylene two-way stopcocks (Qosina, 
Edgewood, NY, USA), connected through tubing to the recording chamber (100 µL), 
where the oocyte was continuously perfused with ND96 recording solution at an 
approximate rate of 5 mL/min.  
 
GABA, etomidate HCl and ZnCl2 were dissolved in ND96 recording solution, whereas 
2′MeO6MF, kavain, allopregnanolone, DS2, propofol, diazepam and flumazenil were 
dissolved in DMSO to make up stock solutions of desired concentrations. GABA stock 
solutions were prepared fresh on the day of experiments. When working with chemicals 
dissolved in DMSO, all perfusates were standardised to contain 0.8 % DMSO, which did 
not produce any alteration in the recordings. Perfusates containing these chemicals were 
made up fresh before each application. The concentration-response curves of agonists 
were obtained by exposing oocytes to increasing concentrations of agonists until the 
currents peaked. Maximal GABA current responses were used as controls to allow for 
comparisons between different oocytes. Depending on the concentration and the 
solubility of the chemicals applied on oocytes, the wash-out periods ranged from 3 to 15 
minutes to allow time for receptors to recover from desensitisation. All experiments were 
performed using at least two different batches of oocytes. 
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2.4.4. Data analysis 
Prism (version 5.04; GraphPad Software, La Jolla, CA, USA) was used for data 
analysis. Raw data from GABA concentration-response experiments were fitted to 
either a monophasic (1) or biphasic (2) Hill equation, and the fitted maximal values 
from the preferred model (Extra sum-of-squares F test) were used for normalisation of 
each dataset.  
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Concentration-response curves of other agonists such as 2′MeO6MF and etomidate were 
constructed in a similar manner, except the data were normalised maximal GABA current 
responses as stated in the relevant chapters. In these equations, Imax represents the 
maximal agonist response, [A] represents the agonist concentration, EC50 represents the 
agonist concentration required to activate 50 % of the maximal response (there are two 
EC50s for a biphasic curve), nH represents the Hill slope of the fitted curve (there are two 
Hill slopes for a biphasic curve), and Frac represents the proportion of the maximal 
response mediated by the more potent component in a biphasic curve. In all cases, the 
bottom was constrained to 0, and when fitting data to the biphasic model, the Hill slopes 
were constrained to 1.  
 
To illustrate the modulatory effect of a chemical of interest, the data were normalised and 
expressed as shown in equation 3, where I represents the current responses elicited by the 
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co-application of GABA and modulator, IGABA represents the amplitude of the control 
GABA-elicited responses. Alternatively, the modulatory effect was expressed as the fold 
of potentiation, as shown in equation 4. 
GABA
GABA
I
II 
………. (3) 
GABA
I
I
…………….. (4) 
 
When comparing parameters across different groups (receptors subtypes/injection ratios), 
the means of the values obtained from individual dataset were analysed using either 
unpaired Student’s t test (comparing means for two groups) or one-way ANOVA with 
Tukey’s post hoc test (comparing every mean with every other mean in three or more 
groups). The ANOVA Dunnett’s test was used when comparing every mean in three or 
more groups to a control mean. Statistical significance was attained at p < 0.05.  
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Chapter 3 
The direct actions of GABA, 2′-methoxy-6-
methylflavone and general anaesthetics at 
β3γ2L GABAA receptors: Evidence for 
receptors with different subunit 
stoichiometries 
______________________________________ 
 
3.1. Introduction 
2′MeO6MF (Figure 1.10B) is a synthetic flavonoid with anxiolytic effect in mice 
behavioural studies [1]. In two unconditioned models of anxiety (elevated plus maze and 
light/dark box tests), 2′MeO6MF (1–10 mg/kg, i.p.) increased exploratory behaviour of 
mice (indicative of anxiolysis) to similar extent as the standard anxiolytic compound 
diazepam (1–2 mg/kg, i.p.). However, unlike diazepam which showed sedative and 
myorelaxant effects within the same dose range, 2′MeO6MF induced sedation only at 
higher doses (30–100 mg/kg) and had no detectable muscle-relaxing action. The 
anxiolytic effect of 2′MeO6MF was found to be attenuated in the presence of the non-
competitive GABAAR antagonist pentylenetetrazole (PTZ), but was unaffected by the 
benzodiazepine site-specific antagonist flumazenil. These data suggest that GABAARs 
may be a possible molecular target for the flavonoid, but the mechanism(s) involved are 
distinct from the benzodiazepines. 
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Single-channel recording experiments investigating 2′MeO6MF activity at native 
receptors in dissociated rat hippocampal neurons confirmed the interaction of 2′MeO6MF 
with GABAARs. In the absence of any ligand, the flavonoid directly elicited current with 
properties consistent with GABAAR-mediated Cl
- current. Furthermore, the co-
application of a competitor peptide mimicking the intracellular MA helix of the GABAAR 
γ2 subunit (residues 381–401) reduced the average current amplitude and open channel 
probability following 2′MeO6MF application (Figure 3.1). The γ2(381-401) MA peptide 
has been shown to selectively reduce diazepam potentiation, possibly by competing with 
the γ2 MA helix to interact with essential proteins involved in ion conductance [2]. It is 
inferred from these data that γ2-containing GABAARs are at least in part responsible for 
the 2′MeO6MF-induced conductance observed in neurons. 
 
 
Figure 3.1. 2′MeO6MF directly activates native γ2-containing GABAARs. The left 
panel traces show the 2 s single-channel activity in excised inside-out patches from 
cultured rat hippocampal neurons, and the right panel shows the current amplitude 
probability histogram obtained from 30 s of continuous activity. (A) Single-channel 
currents elicited by 100 µM 2′MeO6MF had an average maximum amplitude of 2.8 pA. 
(B) The γ2 MA peptide reduced the current amplitude and open channel probability. 
Figure taken from Karim et al. [1]. 
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To determine the subunit requirements for 2′MeO6MF activation, Karim et al. (2012) 
examined the flavonoid activity at numerous recombinant human GABAAR subtypes 
consisting of (α1/2/3/5) + (β1/2/3) +/- (γ2L) subunits [1]. 2′MeO6MF exhibited a complex 
pharmacological profile ranging from positive modulation at all α1-containing and 
α2β1γ2L receptors, activation at α2β2/3γ2L receptors and no activity at α3- and α5-
containing receptors. However, the activity of 2′MeO6MF at βγ receptors was not 
investigated. Flumazenil failed to antagonise the direct activation of 2′MeO6MF at 
GABAARs, in agreement with mice behavioural studies. The distinct activities of 
2′MeO6MF at α2β1γ2L and α2β2/3γ2L receptors resembles that of the general 
anaesthetic etomidate, it was hypothesised that the flavonoid may work via a similar 
mechanism. Consistent with this hypothesis, the homologous residues found on position 
265 of the β subunit, which are critical determinants of etomidate sensitivity at GABAARs 
(the effects of these mutations on etomidate sensitivity are discussed in section 1.11.3), 
were shown to affect 2′MeO6MF activity. Interchanging the asparagine residue of β2 
subunit and the homologous serine residue of β1 subunit resulted in positive modulation 
of α2β2N265Sγ2L receptors and direct activation of α2β1S265Nγ2L receptors. 
 
The non-selective benzodiazepines such as diazepam, while clinically useful in treating 
anxiety, produce undesirable sedative and amnestic effects, and are also associated with 
abuse potential and severe withdrawal symptoms. In contrast, 2′MeO6MF displays clear 
segregation of anxiolytic and sedation doses in mouse behavioural studies and unique 
pharmacological profile at GABAARs which is not related to the benzodiazepines. These 
properties of 2′MeO6MF are deemed more favourable than those of diazepam, and its 
mechanism(s) of action are a topic of interest in our laboratory. However, in our attempt 
to replicate the activity of 2′MeO6MF at α2β3γ2L receptors, we found considerable 
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variations in the efficacy of 2′MeO6MF activation which prompted us to investigate the 
underlying cause(s).  
 
3.2. Results 
3.2.1. Variations in the relative efficacy of 2′MeO6MF activation at 
α2β3γ2L GABAARs  
2′MeO6MF has been previously described as a full agonist at α2β3γ2L GABAARs 
expressed at a 1:1:10 injection ratio in Xenopus oocytes [1]. We expressed α2β3γ2L 
receptors at a 3:1:3 injection ratio and recorded pharmacological responses to GABA, 
Zn2+, diazepam (1 µM) and flumazenil (10 µM) that were consistent with those previously 
reported (Figure 3.2 and Table 3.1) [3-5]. In contrast to what was reported by Karim et 
al. (2012) [1], we found that 300 µM 2′MeO6MF only activated α2β3γ2L receptors 8.2 
± 3.6 % of the 3 mM GABA response (n = 5; Figure 3.2E and F). The EC50 of 2′MeO6MF 
was estimated to be approximately 74 µM (95 % CI: 6.4–850 µM). We hypothesised that 
the variations in the relative efficacy of 2′MeO6MF measured at α2β3γ2L receptors 
expressed at different ratios may be due to the presence of mixed receptor populations.  
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Figure 3.2. Characterisation of α2β3γ2L GABAARs expressed at a 3:1:3 injection 
ratio. (A) Left panel, Representative traces of α2β3γ2L (3:1:3) GABAARs responses to 3 
mM GABA and 100 µM Zn2+ alone. Right panel, Mean holding current of oocytes 
expressing α2β3γ2L (3:1:3) GABAARs (-93 ± 19 nA; n = 8). (B)  Left panel, Continuous 
traces demonstrating two consecutive applications of control (100 µM GABA) followed 
by the co-application of 10 µM Zn2+ with control. Right panel, Modulation of 100 µM 
GABA responses by 10 µM Zn2+ (n = 9). (C) Left panel, Continuous traces demonstrating 
two consecutive applications of control (1 µM GABA) followed by the co-application of 
1 µM diazepam with control; 1 µM diazepam and 10 µM flumazenil with control; and 
control. Right panel, Potentiation by 1 µM diazepam of 1 µM GABA responses (n = 6). 
Representative traces demonstrating (D) GABA current responses from 1 µM to 10 mM 
and (E) 2′MeO6MF’s direct activation from 1 to 300 µM (red) in comparison to 3 mM 
GABA response. Concentration-response curves of GABA (black; n = 6) and 2′MeO6MF 
(red; n = 5) are shown in (F). Data are presented as mean ± SEM. Bars indicate durations 
of drug application. The holding current values are represented by the dotted lines. 
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Table 3.1. Characteristics of receptors expressed in various combinations of α2, β3 
and γ2L GABAAR subunits.  
Subunit 
combination 
Rati
o  
mRNA amount 
(ng/oocyte) 
Expression 
level (nA)a 
Holding 
current (nA) 
n 2′MeO6MF activity n 
α2 ― 28–35 No current -20 ± 7.5 8 No current 5 
β3 ― 5 290 ± 67 -1000 ± 420 6 Inverse agonism 5 
γ2L ― 20–35  No current -370 ± 41 7 No current 5 
α2β3 20:1 5 1100 ± 220 -30 ± 7.0 7 Insignificant activation 5 
α2γ2L 1:1 5 No current -42 ± 16 4 No current 4 
β3γ2L 
1:1 5 110 ± 34 -470 ± 88 4 Inverse agonism 4 
1:5 5 270 ± 80 -220 ± 60 5 Inverse agonism/activation 5 
1:10 5 310 ± 61 -150 ± 13 8 Inverse agonism/activation 8 
1:15 5 490 ± 47 -260 ± 40 30 Activation  30 
1:20 5 860 ± 87  -180 ± 31 49 Activation 49 
1:50 5 1000 ± 160 -28 ± 6.0 15 Activation 15 
1:10
0 
5 1100 ± 100 -15 ± 5.0 21 Activation 21 
α2β3γ2L 
3:1:
3 
5 4300 ± 940 -93 ± 19 8 Activation 5 
a Expression level is expressed as the current responses ± SEM (nA) elicited by 3 mM GABA, except for 
homomeric and α2γ2L receptors  (60 mM GABA).  
 
3.2.2. 2′MeO6MF does not activate binary α2β3 or homomeric α2, β3 
and γ2L GABAARs 
The presence of αβ receptors when expressing αβγ receptors has been shown to result in 
submaximal measurement of diazepam modulation [6, 7] as these receptors lack the α+γ‒ 
interface where diazepam binds. To determine if this was the cause for differences in 
2′MeO6MF relative efficacy at α2β3γ2L receptors, we expressed α2:β3 subunit mRNAs 
at a 20:1 ratio to prevent β3 homomeric receptors from forming, and found that 
2′MeO6MF (100 µM) had negligible activity at these receptors, eliciting currents only 
1.7 ± 0.35 % of the 3 mM GABA responses (n = 5; Figure 3.3A). Therefore, α2β3 
receptors are unlikely to contribute to the much higher 2′MeO6MF relative efficacy 
previously reported at α2β3γ2L GABAARs.  
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Figure 3.3. Subunit combinations with detectable function but were not activated by 
2′MeO6MF. (A) Representative traces illustrating the robust response elicited by 3 mM 
GABA, and the lack of activity of  100 µM Zn2+ and 100 µM 2′MeO6MF at α2β3 (20:1) 
GABAARs (n = 6). (B) The injection of γ2L mRNA at high amounts (28–35 ng/oocyte) 
resulted in constitutively active channels which were inhibited by 100 µM Zn2+, but were 
not sensitive to 60 mM GABA, 100 µM etomidate and 100 µM 2′MeO6MF (n = 5). (C) 
The injection of β3 mRNA (5 ng/oocyte) resulted in the formation of functional receptors. 
Representative traces of β3 homomeric receptors responses to 1–60 mM GABA (top;), 
3–300 µM of 2′MeO6MF and 100 µM Zn2+ (bottom). (D) 2′MeO6MF concentration-
response curve for β3 homomeric receptors (n = 5). The efficacy of 2′MeO6MF as an 
inverse agonist is expressed as a fraction of the inhibited spontaneous current (I) 
normalised against the holding current (Iholding). Data are presented as mean ± SEM. Bars 
indicate durations of drug application. The holding current values are represented by the 
dotted lines. 
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To determine if homomeric GABAARs are activated by 2′MeO6MF, we injected α2, β3 
and γ2L mRNAs alone and examined the effect of 2′MeO6MF at these receptors. We did 
not detect function with 60 mM GABA and 100 µM 2′MeO6MF in Xenopus oocytes 
injected with α2 mRNA (n = 5; Table 3.1). γ2L homomeric receptors showed Zn2+-
sensitive constitutive activity, but were not responsive to 60 mM GABA and 100 µM 
2′MeO6MF (n = 5; Figure 3.3B and Table 3.1). Consistent with previous findings [8, 9], 
the injection of β3 subunit mRNA resulted in the expression of constitutively active 
receptors, which are activated by high concentrations of GABA (Figure 3.3C and Table 
3.1). In contrast to the direct activation observed at α2β3γ2L GABAARs, 2′MeO6MF 
inhibited the constitutive activity of β3 homomeric receptors in a concentration-
dependent manner, with a maximal inhibition of 54 ± 3.0 % (normalised against oocyte 
holding current) measured at 300 µM 2′MeO6MF (n = 5; Figure 3.3C and D). The lack 
of activation by 2′MeO6MF at homomeric receptors demonstrates that these receptors are 
unlikely to be the cause for the variations observed. 
 
3.2.3. 2′MeO6MF activates β3γ2L GABAARs with variable efficacy 
We then determined whether binary α2γ2L or β3γ2L receptors are activated by 
2′MeO6MF. Binary α2γ2L receptors showed no function to 60 mM GABA, 100 µM Zn2+ 
and 100 µM 2′MeO6MF (n = 4; Table 3.1). In contrast, injection of β3 and γ2L mRNAs 
at a 1:20 ratio to prevent the expression of β3 homomers yielded receptors that responded 
to GABA. 2′MeO6MF efficaciously activated these receptors, with 100 µM eliciting 
currents approximately 34 ± 4.0 % of the 3 mM GABA responses (n = 49; Figure 3.4). 
Notably, there was a high variability in the relative efficacy of 2′MeO6MF, ranging from 
as low as 1.0 to 120 % of the 3 mM GABA responses. While the standard error of mean 
efficacy was only 4.0 %, the standard deviation (SD) remained high (31 %). This 
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variability was observed both between different batches of oocytes and within the same 
batch. The substantial variability in the relative efficacy of 2′MeO6MF suggests that the 
1:20 ratio was not optimal for the uniform expression of β3γ2L receptors.  
 
 
Figure 3.4. 2′MeO6MF activity at β3γ2L GABAARs. (A) 2′MeO6MF exhibits a 
complex spectrum of activity across β3γ2L GABAARs expressed at various injection 
ratios. Representative traces of 3 mM GABA (black) and 100 µM 2′MeO6MF (red) are 
shown for each ratio. Bars indicate durations of drug application. The holding current 
values are represented by the dotted lines. (1:1; n = 7), 2′MeO6MF inhibited the 
constitutive activity of receptors expressed. (1:5; n = 5) and (1:10; n = 10), 2′MeO6MF 
exhibited mixed agonist and inverse agonist activity. (1:15; n = 30), 2′MeO6MF directly 
activated receptors expressed efficaciously. (1:20; n = 49), 2′MeO6MF activated β3γ2L 
(1:20) receptors with variable efficacy. Sample traces of cell 1 and 2 were taken from a 
simultaneous experiment conducted on two different oocytes injected at the same time. 
(1:50; n = 15) and (1:100; n = 21), 2′MeO6MF showed activation with low efficacy at 
these receptors. (B) Mean efficacy of 100 µM 2′MeO6MF direct activation at β3γ2L 
(1:15), (1:20), (1:50) and (1:100) GABAARs.  Data are normalised to the 3 mM GABA 
response. The mean efficacy of 100 µM 2′MeO6MF at various ratios was compared using 
Tukey’s test, and the significance levels are indicated with n.s. (not significant) and *** 
(p ≤ 0.001).  
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To establish the optimal ratio(s) for the uniform expression of β3γ2L GABAARs, we 
varied the β3:γ2L mRNAs ratio (1:1, 1:5, 1:10, 1:15, 1:50 and 1:100) while keeping the 
total amount of mRNA constant at 5 ng in each oocyte. We then measured the relative 
efficacy of 100 µM 2′MeO6MF and compared it across these receptors. At 1:1 ratio, 
β3γ2L receptors were constitutively active and 2′MeO6MF acted as an inverse agonist 
(Figure 3.4A). This is likely due to the presence of a substantial amount of β3 homomer 
subpopulation. At 1:5 and 1:10 ratios, where the relative amounts of γ2L mRNA were 
greater than β3 mRNA, 2′MeO6MF displayed a mixed inverse agonist and agonist effect 
(Figure 3.4A), indicating that the pharmacological responses of 2′MeO6MF observed at 
these ratios were still confounded by β3 homomers. 
 
We increased the injection ratio to 1:15, and consistently observed activation with 100 
µM 2′MeO6MF (Figure 3.4A). The 2′MeO6MF-elicited currents were 87 ± 4.5 % of the 
3 mM GABA current responses (n = 30), which was significantly higher than that at 1:20 
ratio (p ≤ 0.001; Tukey’s test; Figure 3.4B). While the low-efficacy component of 
2′MeO6MF was not observed at 1:15 ratio, there was still considerable variability in the 
relative efficacy measured (SD = 25 %). Increasing the injection ratios further to 1:50 and 
1:100 abolished the high-efficacy component of 2′MeO6MF. 100 µM 2′MeO6MF 
showed efficacy around 6.7 ± 1.2 % (n = 15) at 1:50 ratio and 5.1 ± 0.72 % (n = 21) at 
1:100 ratio, which is significantly lower than at the 1:15 ratio (p ≤ 0.001; Tukey’s test; 
Figure 3.4B). The relative efficacy of 2′MeO6MF measured at α2β3γ2L receptors was 
similar to that of β3γ2L receptors expressed at 1:50 and 1:100 ratios (p > 0.5; Dunnett’s 
test), but was significantly lower than 1:15 (p ≤ 0.001) and 1:20 (p ≤ 0.5) ratios. 
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The extensive variability in 2′MeO6MF relative efficacy measured at 1:20 ratio was likely 
to be the result of mixed stoichiometries being expressed. This is further supported by 
variability observed in the GABA concentration-response relationships at β3γ2L (1:20) 
receptors, in which out of 13 datasets, 6 were better fitted to a biphasic Hill equation, 
whereas a simpler monophasic model was preferred to describe the rest of the datasets 
(Figure 3.5). Under our conditions, the 1:15, 1:50 and 1:100 ratios were most optimal to 
express the different stoichiometries of β3γ2L receptors, allowing us to measure 
2′MeO6MF responses more reliably. As such, these ratios were chosen for detailed 
pharmacological characterisation.  
 
Figure 3.5. GABA concentration-response curves of β3γ2L GABAARs expressed at 
1:20 ratio. The experiment was conducted on 13 Xenopus oocytes expressing β3γ2L 
(1:20) receptors, and 6 of the concentration-response curves were found to be better 
fitted to a biphasic Hill equation (left panel), whereas the other 7 datasets prefer a 
simpler monophasic model (middle panel). The unique code for each experiment 
(ddmmyy-cell number) was indicated. The averaged GABA concentration-response 
curve was significantly better fitted to a biphasic model (p < 0.05; extra sum-of-squares 
F test; right panel). EC50_1 = 275 µM; EC50_2 = 17.1 mM; Data are presented as mean ± 
SEM. 
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3.2.4. β3γ2L GABAARs of different subunit stoichiometries vary in 
pharmacological properties 
To obtain an understanding of the properties of different β3γ2L receptor stoichiometries, 
we assessed constitutive activity, 2′MeO6MF and GABA potencies of the receptors 
expressed at 1:15, 1:50 and 1:100 injection ratios. Oocytes expressing β3γ2L (1:15) 
receptors exhibited significantly larger, more negative holding currents (-260 ± 40 nA) in 
comparison to 1:50 (-28 ± 6.0 nA) and 1:100 (-15 ± 5.0 nA) ratios (p ≤ 0.001; Tukey’s 
test; Figure 3.6A). The application of 100 µM Zn2+ generated a reduction in inward 
current at β3γ2L (1:15) receptors (Figure 3.6B). In contrast, 100 µM Zn2+ did not have 
any effect at β3γ2L (1:50) and (1:100) receptors. 
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Figure 3.6. Characterisation of β3γ2L GABAARs expressed at 1:15, 1:50 and 1:100 
ratios. The level of constitutive activity is indicated by (A) holding current of injected 
oocytes and (B) the inhibition of baseline current by 100 µM Zn2+. (A) β3γ2L GABAARs 
expressed at 1:15 ratio showed significantly larger holding current (-260 ± 40 nA; n = 30) 
than at 1:50 (-28 ± 6.0 nA; n = 15) and 1:100 (-15 ± 5.0 nA; n = 21) ratios (p ≤ 0.001; 
Tukey’s test). (B) Representative traces demonstrating current responses of 3 mM 
GABA, 100 µM 2′MeO6MF and 100 µM Zn2+. At 1:15 ratio, receptors were sensitive to 
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the inhibition of 100 µM Zn2+ (reduction in inward current; n = 10). Zn2+ did not have 
any effects at 1:50 (n = 7) and 1:100 (n = 8) ratios. (C) Representative traces 
demonstrating 2′MeO6MF’s direct activation from 1 to 300 µM in comparison to 3 mM 
GABA response. (D) 2′MeO6MF concentration-response curves of β3γ2L (1:15; n = 8), 
(1:50; n = 7) and (1:100; n = 6) GABAARs. Data are normalised to the 3 mM GABA 
response. (E) Representative traces of GABA current responses from 1 µM to 30 mM at 
β3γ2L (1:15), (1:50) and (1:100) GABAARs. (F) GABA concentration-response curves 
of β3γ2L (1:15; n = 6), (1:50; n = 8) and (1:100; n = 9) GABAARs. Data are presented as 
mean ± SEM. Bars indicate durations of drug application. The holding current values are 
represented by the dotted lines.  
 
Despite the difference in maximal efficacy (Figure 3.6C), 2′MeO6MF showed similar 
potency at all ratios (EC50 = 45 µM (1:15), 62 µM (1:50), 63 µM (1:100); p > 0.05 for all 
logEC50 comparisons; Tukey’s test; Figure 3.6D and Table 2). The potency of 
2′MeO6MF measured at α2β3γ2L receptors is also not significantly different from β3γ2L 
receptors at all three ratios (p > 0.05 for all comparisons; Dunnett’s test). We then 
measured the GABA potency, and found that β3γ2L (1:15) receptors displayed a 
monophasic GABA concentration-response curve with low potency and a shallow Hill 
slope (EC50 = 1.4 mM; nH = 0.54; n = 6; Figure 3.6E, F and Table 3.2). In contrast, the 
data of 1:50 and 1:100 ratios were significantly better fitted to a biphasic Hill equation 
than a monophasic model (p < 0.0001 for both ratios; extra sum-of-squares F test; Figure 
3.6E and F). At 1:50 ratio, GABA has a high-sensitivity component with an EC50 of 63 
µM and a low-sensitivity component with an EC50 of 5.5 mM. The mean EC50 values for 
β3γ2L (1:100) receptors were very similar to those of β3γ2L (1:50) receptors (EC50_1: 64 
µM; EC50_2: 4.0 mM). β3γ2L GABAARs expressed at 1:50 and 1:100 ratios exhibit nearly 
identical properties (no statistical significant differences in all aspects; p > 0.05), but are 
very different in comparison to the receptors expressed at 1:15 ratio.  
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Table 3.2. GABA, 2′MeO6MF, etomidate and propofol concentration-response 
curve parameters at β3γ2L (1:15), (1:50) and (1:100) GABAARs derived from curve-
fitting procedures.  
 
 
β3γ2L (ratio)a 
1:15 1:50 1:100 
GABAb 
Imax ± SEMc   780 ± 220 nA 1000 ± 250 nA 1000 ± 97 nA 
EC50_1 (95 % CI) 1.4 (0.87–2.2) mM 63 (47–84) µM 64 (49–83) µM 
EC50_2 (95 % CI) – 5.5 (1.3–23) mM 4.0 (1.4–11) mM 
nH_1 ± SEM 0.54 ± 0.040 1.0 1.0 
nH_2 – 1.0 1.0 
Frac (95 % CI) – 0.74 (0.67–0.80) 0.71 (0.65–0.77)  
n 6 8 9 
2′MeO6MF 
Emax ± SEMd 1.2 ± 0.10 0.086 ± 0.018 0.10  ± 0.020 
EC50 (95 % CI) 45 (31–64) µM 62 (22–172) µM 63 (27–143) µM 
nH ± SEM 1.8 ± 0.42  1.4 ± 0.88   1.6 ± 0.76 
n 8 7 6 
Etomidate 
(-60 mV) 
Emax ± SEMe 20 ± 1.8 5.5 ± 0.80 3.2 ± 0.40 
EC50 (95 % CI) 8.7 (6.7–11) µM 55 (27–110) µM 43 (25–76) µM 
nH ± SEM 2.0 ± 0.32 1.3 ± 0.37 1.5 ± 0.46 
n 5 6 7 
Etomidate 
(-30 mV) 
Emax ± SEMf 9.9 ± 0.84 
N.D.g 
2.8 ± 0.50 
EC50 (95 % CI) 19 (11–31) µM 60 (19–190) µM 
nH ± SEM 1.3 ± 0.33 1.2 ± 0.50 
n 4 5 
Propofol 
Emax ± SEMh 5.7 ± 0.55 
N.D.g 
0.64 ± 0.23 
EC50 (95 % CI) 85 (33–220) µM 74 (33–170) µM 
nH ± SEM 1.4 ± 0.50 2.0 ± 1.2 
n 4 4 
a The total amount of mRNA injected per oocyte was adjusted to be approximately 5 ng for each ratio.   
b Data of 1:15 ratio were better fitted to a monophasic model. Data of 1:50 and 1:100 ratios were 
significantly better fitter to a biphasic model (p < 0.0001 for both ratios; extra sum-of-squares F test). 
Concentration-response curves are shown in Figure 3.6F. 
c Current amplitude elicited by 30 mM GABA. 
d 300 µM 2′MeO6MF-elicited current normalised against 3 mM GABA response.  
e 30 µM (for 1:15) and 300 µM (for 1:50 and 1:100) etomidate-elicited current normalised against 3 mM 
GABA response. 
f 300 µM etomidate-elicited current normalised against 3 mM GABA response. 
g N.D. = not determined. 
h 300 µM propofol-elicited current normalised against 3 mM GABA response. 
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3.2.5. Differential activation of β3γ2L receptors with different subunit 
stoichiometries by general anaesthetics 
2′MeO6MF activity has previously been shown to be affected by a well-established 
mutation that perturbs etomidate activity [1], suggesting that both ligands could share a 
common activation mechanism. Like 2′MeO6MF, etomidate did not activate homomeric 
2L (Figure 3.3B) or 22L receptors (n = 4; data not shown). However, etomidate 
activated β3 homomeric receptors efficaciously (Emax = 15 ± 0.79, normalised against 60 
mM GABA), with an EC50 of 7.7 µM (95 % CI: 5.6–11 µM; n = 5; Figure 3.7E and F), 
in contrast to 2′MeO6MF inhibition of the receptors’ constitutive activity (Figure 3.3C). 
 
We then evaluated etomidate at β3γ2L (1:15), (1:50) and (1:100) receptors. Etomidate 
directly activated β3γ2L receptors expressed at all three ratios, albeit with different 
relative efficacies (Figure 3.7A). At 10 µM, etomidate directly activated β3γ2L (1:15) 
approximately 12 ± 1.1 fold higher relative to 3 mM GABA (n = 7), significantly greater 
than at 1:50 (0.46 ± 0.10; n = 6) and 1:100 (0.27 ± 0.05; n = 7) ratios (p ≤ 0.001; Tukey’s 
test; Figure 3.7B). At β3γ2L (1:50) and (1:100) receptors, consistent with the almost 
identical GABA and 2′MeO6MF profiles, etomidate activated β3γ2L receptors at both 
ratios with no significant differences in potencies and maximal efficacies (p > 0.05; 
unpaired t test; Figure 3.7C and Table 3.2). At 1:15 ratio, we could not construct a 
complete concentration-response curve as the current elicited by etomidate at 
concentrations above 10 µM frequently exceeded the measuring range of the amplifier (> 
10 µA).  
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Figure 3.7. Etomidate activates both β3γ2L and β3 GABAARs. (A) Representative 
traces of etomidate (10 µM) direct activation in comparison to 3 mM GABA at β3γ2L 
(1:15), (1:50) and (1:100) GABAARs. (B) Mean efficacy of 10 µM etomidate activation 
at β3γ2L (1:15; n = 7), (1:50; n = 6) and (1:100; n = 7) receptors. Data are normalised to 
the 3 mM GABA response. The mean efficacy of 10 µM etomidate at various ratios was 
compared using Tukey’s test, and the significance levels are indicated with n.s. (not 
significant) and *** (p ≤ 0.001). (C) Concentration-response curves of etomidate 
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activation at β3γ2L receptors expressed at 1:15 (n = 5), 1:50 (n = 6) and 1:100 (n = 7) 
ratios. Recording was conducted at -60 mV. Data are normalised to the 3 mM GABA 
response. (D) Concentration-response curves of etomidate activation at β3γ2L receptors 
expressed at 1:15 (n = 4) and 1:100 (n = 5) ratios. Recording was conducted at -30 mV. 
Data are normalised to the 3 mM GABA response. (E) Representative traces of β3 
homomeric receptors responses to 0.1–300 µM etomidate in comparison to 60 mM 
GABA response. (F) Etomidate concentration-response curve for β3 homomeric 
receptors (n = 5). Data are normalised against 60 mM GABA responses. Data are 
presented as mean ± SEM. Bars indicate durations of drug application. 
 
To investigate etomidate activity across the whole concentration range at β3γ2L (1:15) 
receptors, we conducted electrophysiological recording at -30 mV. The same experiment 
was repeated at β3γ2L (1:100) receptors as a control. As expected from the voltage-
dependent profile of etomidate [10], we observed reduced etomidate activation at -30 mV. 
However, etomidate still exhibited significantly larger relative efficacy at 1:15 (9.9 ± 
0.84) than 1:100 (2.8 ± 0.50) ratio (p ≤ 0.01; unpaired t test; Figure 3.7D; Table 3.2). 
Etomidate also showed a modest, but significantly higher potency at 1:15 (EC50 = 19 µM) 
than 1:100 (EC50 = 60 µM) ratio (p ≤ 0.01 for logEC50 comparison; unpaired t test; Table 
3.2). 
 
We also investigated the action of propofol, a non-selective general anaesthetic which has 
been shown to bind with similar affinity to at least 4 binding sites at GABAARs found on 
β+α‒, α+β‒, β+β‒ and γ+β‒ subunit interfaces [11, 12]. We found that propofol directly 
activated β3γ2L receptors, in agreement with previous findings reported on β2γ2S 
receptors [13]. Like etomidate, propofol directly activated β3γ2L (1:15) and (1:100) 
receptors differentially (Figure 3.8A). At 300 µM, propofol elicited current responses 
approximately 6-fold larger than maximal GABA currents at β3γ2L (1:15) receptors, 
significantly larger than at β3γ2L (1:100) receptors (Emax = 0.64 ± 0.23; p ≤ 0.001; 
unpaired t test; Figure 3.8B; Table 3.2). However, the potencies of propofol measured at 
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1:15 (EC50 = 85 µM) and 1:100 (EC50 = 74 µM) ratios were not different (p > 0.05; 
unpaired t test; Table 3.2). 
 
 
Figure 3.8. Propofol activates β3γ2L (1:15) and (1:100) receptors with different 
relative efficacies. (A) Representative traces of propofol (1–300 µM) direct activation in 
comparison to 3 mM GABA at β3γ2L (1:15) and (1:100) GABAARs. (B) Concentration-
response curves of propofol activation at β3γ2L receptors expressed at 1:15 (n = 4) and 
1:100 (n = 4) ratios. Data are normalised to the 3 mM GABA response.   
  
3.3. Discussion 
2′MeO6MF has been previously demonstrated to directly activate recombinant 
α2β2/3γ2L GABAARs expressed in Xenopus oocytes [1], but the functional significance 
of each subunit remains unclear. In this study, we performed a systematic investigation 
of 2′MeO6MF activity at all receptor combinations expressed in Xenopus oocytes using 
α2, β3 and γ2L subunits and found that 2′MeO6MF exhibits distinct pharmacology at β3, 
β3γ2L and α2β3γ2L GABAARs. It acts as an inverse agonist at β3 homomers by inhibiting 
the constitutive activity of the receptors, and activates β3γ2L and α2β3γ2L GABAARs 
with different relative efficacies. The lack of activity of 2′MeO6MF at α2β3 (20:1) binary 
receptors, despite the presence of the β3 subunit, favours an interfacial 2′MeO6MF 
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binding site(s) containing the β3 subunit (β3-β3, β3-γ2L or γ2L-β3) over an intra-β3-
subunit binding site.  
 
The robust formation of the non-α-containing β3γ2L GABAARs raises a critical question 
of where GABA binds to activate this receptor as it lacks the β+α‒ interfaces. Despite the 
absence of any known GABA binding sites in β3γ2L receptors, GABA elicited robust 
responses within a similar concentration range that activates αβ and αβγ receptors. Thus, 
we infer that GABA binding site(s) which are previously unknown may exist. A GABA 
binding site at the β-β interface is possible, but the poor GABA activity at β3 homomeric 
receptors even at saturating concentrations suggests that other subunit interfaces, possibly 
between the β and γ subunits are more likely to contribute to the GABA sensitivity of 
β3γ2L receptors.  
 
There is a wealth of evidence supporting two β+α‒ interfacial binding sites for etomidate 
in the transmembrane domain [14-16]. Our data show that etomidate activates β3 
homomeric and β3γ2L binary receptors efficaciously, but is insensitive at γ2L homomeric 
receptors. These findings indicate that the β, but not the α subunit is essential for 
etomidate sensitivity. This is supported by findings from a photoaffinity labelling study 
which suggested that etomidate can also bind to a homologous β+β‒ interfacial site with 
less selectivity [12]. Besides that, mutations found on the β subunit such as N265M [17] 
and M286W [18] have been shown to completely eliminate etomidate sensitivity, while 
mutations found on the α subunit tend to have less profound effects [19]. Taken together, 
we infer from these findings that the β subunit, which bears the principal (+) components 
of the etomidate binding sites, dominates ligand binding interactions, whereas the identity 
of the complementary (‒) subunit (α, β or γ) is well tolerated. 
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We also demonstrate that β3γ2L receptors expressed at different injection ratios exhibit 
distinct levels of constitutive activity, relative efficacies of 2′MeO6MF, etomidate and 
propofol activation as well as different GABA potencies. These findings strongly suggest 
that β3γ2L receptors with different subunit stoichiometries are being formed. The 
influence of subunit cDNA or mRNA ratios on receptor stoichiometry expressed in 
heterologous systems is well established in the case of α4β2 nicotinic acetylcholine 
receptors, in which α4-biased and β2-biased ratios are routinely used to selectively 
express the pharmacologically dissimilar 3(α4):2(β2) and 2(α4):3(β2) stoichiometries 
respectively [20, 21]. It is not clear from our experiments which stoichiometries of β3γ2L 
receptors exist. However, as the binary αβ GABAARs have been shown to assemble into 
two functional stoichiometries of 2α:3β and 3α:2β [22-24], by analogy, we propose that 
β3γ2L GABAARs also exist in two different stoichiometries of 3β:2γ and 2β:3γ. It is likely 
that when the γ2L subunit mRNA was injected in greater abundance relative to the β3 
subunit (e.g., 1:50 and 1:100 ratios), the 2β:3γ stoichiometry is predominantly expressed. 
In contrast, when the injection ratio was reduced (e.g., 1:15), the 3β:2γ stoichiometry may 
be favourably expressed. The definitive mechanisms underlying the distinct 
pharmacological profiles of β3γ2L stoichiometric forms are beyond the scope of this 
investigation, but differences in the number of functional binding interfaces and intrinsic 
activation properties may have a role. Further experiments are required to understand how 
these factors result in the complex pharmacology observed for β3γ2L receptors. 
 
We and others have shown that 2′MeO6MF, etomidate, pentobarbital and dopamine 
appear to be more efficacious agonists than GABA at β3γ2 receptors [25, 26]. In contrast, 
these ligands directly activate αβγ receptors with lower efficacies relative to the maximal 
GABA responses [18, 26, 27]. Similar observations have been reported at αβδ receptors, 
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where GABA acts as a partial agonist with low intrinsic efficacy, and modulators such as 
neurosteroids [28], etomidate [29], propofol [30] and pentobarbital [27] are able to 
enhance maximal GABA currents significantly larger than they do at αβγ receptors, where 
GABA acts as a full agonist. It is possible that GABA also acts as a weak partial agonist 
at βγ receptors. However, this inference is not conclusive as the intrinsic efficacies of 
GABA and other ligands at βγ receptors are not well established and were not 
systematically explored in our study. Further studies are required to address these issues, 
and to clarify whether the apparent larger relative efficacies of various ligands at βγ 
receptors are due to subtype-dependent functional differences or the low GABA efficacy 
at these channels. 
  
The expression of βγ receptors has been reported previously [13, 25, 26, 31-34]. In these 
studies, the overall pharmacological profiles of βγ receptors are very similar to that of the 
αβγ receptors. This is concerning as pharmacological tools such as diazepam, which is 
routinely used as an indicator of the purity of the αβγ receptors heterologously expressed 
would not be able to distinguish βγ from αβγ receptors due to its comparable actions at 
both receptor subtypes [31, 33]. The GABAAR competitive antagonist bicuculline has 
recently been suggested to have β3γ2-selective pharmacology as it exhibits inhibitory 
action at α1β3γ2 but activates β3γ2 receptors [26]. However, as bicuculline has been 
shown to also activate β3 homomers [8], it is not known if the effect observed at β3γ2 
receptors was mediated by a background population of β3 homomers. The great diversity 
in GABAAR subtypes dictates the need for subtype-specific ligands to understand the 
function of these receptors. As such, the search for βγ-selective ligands is pivotal to 
accurately determine the pharmacology of these receptors in vitro. 
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There is emerging evidence to suggest that native GABAAR subtypes are far more diverse 
than earlier studies have indicated, as exemplified by the in vivo expression of αβ 
receptors which were previously thought to only form in heterologous systems [35-39]. 
In single channel recording experiments conducted in dissociated rat hippocampal 
neurons, it has been shown that the activity of 2′MeO6MF, like diazepam, is significantly 
attenuated by the γ2(381-403) MA peptide which disrupts protein-receptor interactions 
involving only the γ2 subunit [1, 2]. This finding suggests that γ2-containing GABAARs 
are the molecular target of 2′MeO6MF, and the subunit composition of these receptors is 
most likely to make up of α, β and γ subunits since they are the most common native 
isoforms. It is currently not known if βγ receptors exist in neurons and thus contribute 
partially to the flavonoid activation observed. Again, βγ-selective ligands will be 
necessary to explore this possibility.  
 
Overall, our findings have important implications in the study of GABAARs. We have 
shown that β3γ2L receptors assemble with different subunit stoichiometries in Xenopus 
oocytes, which can be differentiated by GABA, 2’MeO6MF, etomidate and propofol. 
These receptors lack the α subunit which contributes the complementary (‒) components 
of the GABA and etomidate binding sites, but are still activated by GABA and etomidate, 
suggesting that the structural requirements for these sites need to be redefined. While the 
in vivo existence of βγ receptors remains elusive, it can serve as a tool to study the 
contribution of different subunits or subunit interfaces in the pharmacology of a chemical 
of interest. 
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Chapter 4 
The modulation of recombinant GABAARs 
by kavain, the major constituent of the 
anxiolytic kava extract is attenuated by the 
β3N265M point mutation 
______________________________________ 
 
4.1. Introduction  
The use of intoxicating substances to enhance mood, alter consciousness and to achieve 
spiritual enlightenment is known in virtually every culture. Alcohol is the most commonly 
used intoxicant globally, with the exception in a few regions [1]. For millennia, Pacific 
Islanders have been using the root of a native pepper plant called kava (Piper 
methysticum) to prepare a non-alcoholic psychoactive beverage, which is also called 
kava. Kava drinking is an integral component of the Pacific Islander culture, with kava 
playing roles as a sacred drug in religious rituals, a social lubricant at formal gatherings, 
and a medicine to induce relaxation and sleep [2]. The contemporary use of kava extends 
beyond ritualised circumstances [3, 4]. In some western societies, kava is used as a 
prescription-free alternative to the benzodiazepines to relieve stress-induced anxiety and 
insomnia [5]. The recreational use of kava as a substitute for alcohol is also gaining 
popularity owing to kava’s calming effect which contrasts the aggressive tendencies 
associated with alcohol [6]. 
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There is a long-standing interest in the use of kava in the treatment of anxiety. In clinical 
trials, kava extracts are superior to placebo in reducing anxiety, and are generally well 
tolerated with negligible to mild side effects [7-9]. Despite reports of alleged kava-
induced hepatotoxicity which led to the withdrawal and restriction of kava in several 
countries [10, 11], systematic reviews and meta-analyses conducted over the last 15 years 
found a clear positive benefit-to-risk ratio for kava [12, 13]. In view of the lack of direct 
causal evidence for liver injury, the ban of kava in Germany was recently overturned, 
leading to a resurgence of attention on kava [14]. Currently, there is an ongoing phase III 
clinical trial aimed to establish the efficacy and safety of kava in patients diagnosed with 
generalised anxiety disorder [15]. 
 
A group of structurally-related, lipophilic compounds known as kavalactones (or 
kavapyrones) is responsible for the clinical effects of kava [16]. Kavain, along with 
dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyangonin are 
the most abundant kavalactones (Figure 4.1) [17]. Numerous proteins including 
GABAARs, voltage-gated Na
+ and Ca2+ channels, opioid µ and δ receptors, dopamine 
type-2 (D2) receptor, histamine type-1 and 2 (H1/2) receptors, cannabinoid type-1 (CB1) 
receptor, and monoamine oxidase type B (MAO-B) have been suggested to be the 
molecular targets for kavalactones [16, 18-20]. However, due to the paucity in robust 
evidence, a consensus on the pharmacology of kavalactones could not be reached.  
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Figure 4.1. Chemical structures of the six major kavalactones found in kava. 
 
The prevailing view that GABAARs are a strong candidate target for kavalactones is on 
the basis of their benzodiazepine-like pharmacological actions. To date, evidence that 
indicates kavalactone-GABAAR interaction mainly comes from radioligand binding 
studies. In rodent brain membranes, kava extracts with enriched kavalactone content were 
able to enhance the binding of radiolabelled orthosteric ligands to native GABAARs [19, 
21]. The interaction of pure kavalactones with GABAARs has also been investigated, but 
mixed results were obtained. Davies et al. (1992) demonstrated that kavalactones only 
enhanced [3H]GABA binding marginally even at high concentrations (up to 1 mM) [22]. 
The removal of lipid membrane with detergent resulted in the complete loss of 
modulation, a finding that prompted the authors to speculate that kavalactones, due to 
their lipophilicity, alter the physicochemical properties of lipid membrane to cause 
conformational changes in GABAARs [22]. However, another study found that pure 
kavalactones showed low-micromolar affinity and structure-dependent activity at 
GABAARs, implying that kavalactones do directly bind to GABAARs [23]. Notably, none 
of these studies detected significant affinity of kavalactones for the benzodiazepine 
binding site, contrary to popular belief. 
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There is limited information on kavalactone mechanism of action provided by these 
studies due to two factors. First, the contribution of non-kavalactone compounds in 
enhancing ligand binding cannot be ruled out with the use of kava extracts in some 
studies. Second, kavalactones were tested on a heterogeneous population of GABAARs 
isolated from rodent brain, thus the identity of specific GABAAR subtypes modulated by 
kavalactones is not known. To address these limitations, in this study, we set out to 
perform functional characterisation of a kavalactone at 9 different GABAAR subtypes 
expressed in Xenopus oocytes. Kavain is selected as the representative kavalactone due 
to its abundance in kava extracts commonly consumed [24], as well as its established 
anxiolytic and sedative properties in animal and human [25-27].  
 
4.2. Materials and Methods 
4.2.1. Primer sequences used in site-directed mutagenesis 
The protocol of site-directed mutagenesis is detailed in section 2.4.1.8. Primers used for 
the generation of desired mutations in different GABAAR subunits are shown in Table 
4.1, with the nucleotides coding for the mutations underlined: 
 
Table 4.1. Primers used to introduce the α1M236W, β2M286W, and β3N265M point 
mutations. 
Mutations Primers 
α1M236W 
Forward: CCTGCCGTGCATATGGACAGTTATTCTC 
Reverse: GAGAATAACTGTCCATATGCACGGCAGG 
β2M286W 
Forward: AGGCCATTGACATGTACCTGTGGGGGTGCTTTGTCTTCGT 
Reverse: ACGAAGACAAAGCACCCCCACAGGTACATGTCAATGGCCT 
β3N265M 
Forward: ACAATGACAACCATCATGACCCACCTTCGGGAG 
Reverse: CTCCCGAAGGTGGGTCATGATGGTTGTCATTGT 
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4.2.2. Electrophysiological studies 
The subunit mRNA ratios, and the total amount of mRNA injected into individual oocyte 
used for the expression of various GABAAR subtypes in this study are listed in Table 4.2. 
The screening of kavain at α2/3β2γ2L GABAARs was performed by Kirsten Høstgaard-
Jensen from the Department of Drug Design and Pharmacology, University of 
Copenhagen, Denmark. 
 
Table 4.2. Subunit mRNA ratios used to express different GABAAR subtypes. 
Subunit combination Ratio mRNA amount (ng/oocyte) 
α1β2 1:1 10 
β2γ2L 1:3 10 
α1β2γ2L 1:1:3 2.5 
α5β2γ2L 1:1:3 1.5 
α1β1γ2L 5:1:5a 5  
α1β3γ2L 10:1:10a 1.5 
α4β2δb 5:1:5 6 
α1M236Wβ2γ2L 1:1:3 2.5 
α1β2M286Wγ2L 1:1:3 2.5 
α1β3N265Mγ2L 10:1:10a 1.5 
a The α1 and γ2L subunit mRNAs are in excess to reduce the expression of homomeric β1/3 receptors. 
b The mRNA mixture was a generous gift from Leonny Hartidi who characterised the pharmacological 
profiles of α4β2δ receptors expressed at different injection ratios. The 5:1:5 ratio was found to give rise 
to a relatively homogeneous receptor population in Xenopus oocytes with consistent pharmacology [28]. 
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4.3. Results 
4.3.1. Effect of GABAAR subunit composition on kavain activity 
We tested kavain (10–300 µM) at α1β2γ2L GABAARs, the most abundant native 
GABAAR isoform, in the presence of GABA EC3 (10 µM), and found that kavain 
enhances GABA-elicited responses in a concentration-dependent manner (Figure 4.2A). 
The modulatory effect of kavain is moderate, with only 170 ± 23 % of enhancement 
measured at 300 µM (n = 6; Figure 4.2C). We also investigated the ability of kavain to 
activate the receptors, and found negligible agonist activity, with 300 µM kavain eliciting 
currents < 1 % of the 10 mM GABA responses (n = 5; Figure 4.2B). To understand the 
subunit requirement for kavain modulation, we tested kavain (10–300 µM) at different 
GABAAR subtypes with a low concentration of GABA (EC3-7 for all receptors except 
α4β2δ, where the EC30 was used due to the low level of expression). The receptor 
subtypes investigated were α1β2, β2γ2L, αxβ2γ2L (x = 1, 2, 3 or 5), α1βxγ2L (x = 1, 2 
or 3) and α4β2δ (GABA concentration-response relationships summarised in Figure 4.3 
and Table 4.3). Kavain potentiated current responses elicited by low concentrations of 
GABA at all receptors to a similar degree, exhibiting no apparent subtype selectivity (no 
significant difference was detected for all pairwise comparisons using Tukey’s test; p > 
0.5; Figure 4.2C).  
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Figure 4.2. Kavain potentiates GABAARs with no apparent subtype selectivity. (A) 
Representative traces demonstrating kavain (10–300 µM) enhancing current elicited by 
10 µM GABA (EC3) at α1β2γ2L GABAARs in a concentration-dependent manner. (B) 
Representative traces of current responses elicited by a maximal concentration of GABA 
(10 mM), in comparison to 300 µM kavain alone. (C) Top panel, Potentiation of GABA 
EC3-7 by 300 µM kavain at α1β2, β2γ2L, αxβ2γ2L (x = 1, 2, 3 and 5) and α1βxγ2L (x = 
1, 2 and 3) GABAARs. At α4β2δ GABAARs, the GABA control (1 µM) corresponds to 
an EC30. Data are presented as mean ± SEM. Numbers in bars indicate the number of 
experiments. No significant difference was found for kavain potentiation at these receptor 
subtypes (Tukey’s test; p > 0.05 for all pairwise comparisons). Bottom panel, 
Superimposed current traces of GABA alone (black) and GABA in combination with 300 
µM kavain (red) at the corresponding receptor subtypes. The black bars above the traces 
indicate duration of drug application.  
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Figure 4.3. GABA concentration-response curves for all receptor subtypes 
expressed in this study. Data are presented as mean ± SEM. The curve parameters are 
listed in Table 4.3. 
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Table 4.3. GABA concentration-response curve parameters at various receptor 
subtypes derived from curve-fitting procedures. 
Receptor subtypes GABA EC50 (95% CI) nH ± SEM n 
α1β2 7.8 (6.9–8.8) µM 1.2 ± 0.072 5 
β2γ2L 1.3 (0.9–1.8) mM 0.63 ± 0.034  4 
α1β2γ2L  136 (116–158) µM 0.99 ± 0.062 10 
α1β2γ2L (+ 300 µM kavain) 99 (87–113) µMa 0.75 ± 0.026 6 
α2β2γ2L 76 (72–80) µM 1.4 ± 0.041 4 
α3β2γ2L 150 (136–162) µM 1.2 ± 0.054 4 
α5β2γ2L 67 (56–80) µM 1.0 ± 0.078 5 
α1β1γ2L 89 (79–100) µM 1.1 ± 0.059 6 
α1β3γ2L 93 (83–104) µM 1.2 ± 0.070 5 
α4β2δ 2.6 (1.7–4.1) µM 0.70 ± 0.095 4 
α4β2δ (+ 300 µM kavain) 1.7 (0.93–3.1) µMa 0.59 ± 0.11 4 
α1M286Wβ2γ2L 59 (48–73) µM**b 0.80 ± 0.053 7 
α1β2M286Wγ2L 25 (23–27) µM****b 1.1 ± 0.036 5 
α1β3N265Mγ2L 72 (65–80) µMc 1.4 ± 0.083 5 
a The GABA potency was not significantly altered in the presence of 300 µM kavain (p > 0.05 for logEC50 
comparisons; paired t test). 
b The GABA potency was significantly enhanced compared to wild-type α1β2γ2L GABAARs (** p < 0.01; 
**** p < 0.0001 for logEC50 comparisons; unpaired t test). 
c
 The GABA potency was not significantly different from the wild-type α1β3γ2L GABAARs (p > 0.05 for 
logEC50 comparisons; unpaired t test). 
 
4.3.2. Kavain’s differential effects at α1β2γ2L and α4β2δ GABAARs 
To understand the nature of kavain modulation in response to different GABA 
concentrations, we constructed GABA concentration-response curves with and without 
300 µM kavain at α1β2γ2L and α4β2δ receptors. These receptors represent synaptic and 
extrasynaptic GABAARs respectively, which have distinct subcellular localisations 
(section 1.9) and GABA sensitivities (α1β2γ2L: EC50 = 136 µM; α4β2δ: EC50 = 2.6 µM; 
Figure 4.3; Table 4.3). At α1β2γ2L receptors, kavain showed modest enhancement at 
GABA concentrations below EC45, but did not affect the EC50 and maximal efficacy of 
GABA (p > 0.05 for both parameters; paired t test; Figure 4.4A and D; Table 4.3). In 
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contrast, kavain increased the maximal GABA efficacy by two fold (p < 0.0001; paired t 
test) at α4β2δ receptors without affecting the GABA potency (p > 0.05 for logEC50 
comparison; paired t test; Figure 4.4B and D; Table 4.3). 
 
 
Figure 4.4. Kavain produced greater enhancement of GABA-elicited currents at 
α4β2δ than α1β2γ2L GABAARs. (A) GABA concentration-response curves in the 
absence (black; n = 10) and presence (red; n = 6) of 300 µM kavain at α1β2γ2L 
GABAARs. The curve parameters are summarised in Table 4.3. (B) GABA 
concentration-response curves in the absence (black; n = 4) and presence (red; n = 4) of 
300 µM kavain at α4β2δ GABAARs. The curve parameters are summarised in Table 4.3. 
(C) Superimposed current responses of maximal GABA in the absence (black) and 
presence (red) of 300 µM kavain at α1β2γ2L and α4β2δ GABAARs. (D) The effect of 
kavain on the maximal GABA current responses at α1β2γ2L (n = 6) and α4β2δ (n = 7) 
GABAARs was compared using the paired t test, and the significance levels are indicated 
with n.s. (not significant) and **** (p < 0.0001). Data are presented as mean ± SEM.  
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4.3.3. Effect of membrane potential on kavain modulation 
The activity of some GABAAR modulators is known to be voltage dependent. For 
instance, anaesthetic agents such as etomidate, propofol and isoflurane exhibit greater 
potentiation at negative membrane potentials, and the effect decreases as the membrane 
potentials become more positive [29]. To determine if kavain also shows voltage 
dependence, the enhancement of 10 µM GABA (EC3) responses mediated by 300 µM 
kavain across a range of membrane potentials (-80 to -30 mV, applied as 10 mV steps) 
was measured at α1β2γ2L GABAARs. We found that changes in membrane potential had 
no significant effect on kavain modulation (p > 0.05 for all pairwise comparisons; 
Tukey’s test; n = 6–9 for each data point; Figure 4.5).  
 
 
Figure 4.5. Membrane potential has negligible effect on the degree of potentiation of 
kavain. (A) Representative traces demonstrating the current responses to 10 µM GABA 
(EC3) alone and the co-application of 10 µM GABA and 300 µM kavain when the 
membrane potential at which the oocyte was voltage-clamped was changed from -80 to -
30 mV in 10 mV steps at α1β2γ2L GABAARs. (B) Potentiation of GABA EC3 by 300 
µM kavain at α1β2γ2L GABAARs plotted against the holding potential. No significant 
difference was found for kavain potentiation at different membrane potential (Tukey’s 
test; p > 0.05 for all pairwise comparisons). Data are presented as mean ± SEM. n = 6–9 
for each data point.  
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4.3.4.   Interaction of kavain with various allosteric binding sites  
The psychoactive properties of kavalactones have sparked concern of potential adverse 
pharmacodynamic interactions with the co-administration of kava with other CNS 
depressants, but there is a lack of experimental evidence to support these postulations 
[30]. Thus, we sought to determine whether kavain interacts with other GABAAR 
allosteric modulators in an additive, synergistic or antagonistic manner. 
 
4.3.4.1.  Benzodiazepines 
We investigated the effect of combining benzodiazepine site ligands with kavain at 
α1β2γ2L GABAARs (n = 5; Figure 4.6). In concordance with the literature, diazepam (1 
µM) enhanced current responses elicited by 10 µM GABA in a flumazenil-sensitive 
manner, and flumazenil alone did not alter GABA responses, consistent with its 
neutralising modulator profile [31]. Unlike diazepam, the GABA-enhancing action of 300 
µM kavain was unaffected in the presence of flumazenil. We also found that the co-
application of kavain and diazepam resulted in significantly greater enhancement of 
GABA current (350 ± 10 %) compared to their actions alone (GABA + diazepam: 260 ± 
4.2 %, p < 0.001; GABA + kavain: 260 ± 11 %, p < 0.0001; paired t test; Figure 4.6B). 
However, this degree of potentiation was less than additive (theoretical additive value = 
420 %). The same experiment was repeated with 100 nM diazepam, and a less-than-
additive interaction was detected again with the kava and diazepam combination (n = 3; 
data not shown). 
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Figure 4.6. Flumazenil-insensitive kavain potentiation has less-than-additive effect 
on diazepam action. Top, Representative traces demonstrating responses to control (10 
µM GABA); control and 1 µM diazepam; control, 1 µM diazepam and 10 µM flumazenil; 
control and 10 µM flumazenil; control and 300 µM kavain; control, 300 µM kavain and 
10 µM flumazenil; and control, 300 µM kavain and 1 µM diazepam. Bottom, The 
modulatory effect of diazepam, flumazenil and kavain at α1β2γ2L GABAARs (n = 5). 
Kavain potentiation was unchanged in the presence of flumazenil (G + K vs. G + K + F; 
p > 0.05; paired t test). The combination of kavain and diazepam (G + K + D) resulted in 
greater potentiation than diazepam (G + D; p < 0.001; paired t test) and kavain (G + K; p 
< 0.0001; paired t test) alone, but the effect was less than the theoretical additive 
modulatory effect (dotted line). Data are normalised to the current responses elicited by 
10 µM GABA, and are presented as mean ± SEM.  
 
4.3.4.2.  Allopregnanolone 
Next, we investigated the interaction of kavain with the neurosteroid allopregnanolone at 
α1β2γ2L GABAARs (n = 5; Figure 4.7). At 1 µM, allopregnanolone enhanced GABA 
EC3 responses efficaciously to 730 ± 62 %. Co-application of allopregnanolone with 300 
µM kavain did not result in a significant increase in enhancement (840 ± 60 %; p > 0.05; 
paired t test; Figure 4.7B). As we failed to detect agonist activity with allopregnanolone 
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even at 30 µM, in agreement with Hammer et al. [32], the presence of the neurosteroid 
activation site previously reported [33] could not be ascertained under our experimental 
conditions. Thus, the interaction of kavain with the neurosteroid activation site was not 
explored. 
 
Figure 4.7. The lack of effect of kavain on allopregnanolone potentiation at α1β2γ2L 
GABAARs. Top, Representative traces demonstrating the current responses elicited by 
10 µM GABA (control); control with 300 µM kavain; control with 1 µM 
allopregnanolone; and control, 300 µM kavain and 1 µM allopregnanolone. Bottom, The 
modulatory effect of kavain and allopregnanolone (n = 5). The degree of potentiation 
elicited by allopregnanolone alone is not significantly different from that of the co-
application of allopregnanolone and kavain (G + A vs. G + K + A; p > 0.05; paired t test; 
n.s. = not significant). Data are normalised to the 10 µM GABA responses, and are 
presented as mean ± SEM. 
 
4.3.4.3.  DS2 
We also investigated the modulatory effect of kavain and DS2, either alone or in 
combination on the maximal GABA responses (1 mM) at α4β2δ GABAARs (n = 7; 
Figure 4.8). 300 µM kavain and 1 µM DS2 enhanced the GABA responses by 200 ± 11 
% and 380 ± 32 % respectively (Figure 4.8B). Co-application of 300 µM kavain and 1 
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µM DS2 resulted in 400 ± 29 % potentiation, which was not significantly different from 
the degree of potentiation elicited from 1 µM DS2 alone (p > 0.05; paired t test; Figure 
4.8B). 
  
 
Figure 4.8. The lack of effect of kavain on DS2 potentiation at α4β2δ GABAARs. Top, 
Representative traces demonstrating the current responses elicited by 1 mM GABA 
(control); control with 300 µM kavain; control with 1 µM DS2; and control, 300 µM 
kavain and 1 µM DS2. Bottom, The modulatory effect of kavain and DS2 alone and in 
combination (n = 7). The degree of potentiation elicited by DS2 alone is not significantly 
different from that of the co-application of kavain and DS2 (G + DS2 vs. G + K + DS2; 
p > 0.05; paired t test; n.s. = not significant). Data are normalised to the 1 mM GABA 
responses, and are presented as mean ± SEM. 
 
 
 
 
117 
 
 
4.3.4.4.  General anaesthetics 
The effect of combining kavain and general anaesthetics (etomidate and propofol) on 
receptor modulation was also investigated at α1β2γ2L GABAARs. Both a low and a high 
concentration of the general anaesthetics were used (3 and 30 µM for etomidate; 10 and 
100 µM for propofol) to produce the modulatory and agonist effects respectively. 
 
Etomidate 
At 3 µM, etomidate enhanced the GABA EC3 responses efficaciously (53 ± 2.6 % of 
maximal GABA responses; n =7; Figure 4.9). The addition of 300 µM kavain resulted in 
a modest, but significant reduction in potentiation (45 ± 3.1 % of maximal GABA 
responses; n = 7; p < 0.01; paired t test). At 30 µM, etomidate directly elicited current 
responses approximately 24 ± 4.2 % of the maximal GABA amplitude (n = 6). The agonist 
effect was not significantly altered in the presence of 300 µM kavain (27 ± 2.8 %; n = 6; 
p > 0.05; paired t test). 
 
Propofol 
At 10 µM, propofol enhanced the GABA EC3 responses efficaciously (45 ± 3.5 % of the 
maximal GABA responses; n =5; Figure 4.10). The addition of 300 µM kavain resulted 
in a slight, but insignificant enhancement in propofol potentiation (50 ± 4.8 %; p > 0.05; 
paired t test). Following exposure to 100 µM propofol, GABA-elicited current responses 
were highly variable, resulting in inconsistent measurement. Thus, the agonist effect of 
propofol was investigated in the absence of GABA. We found that when combined, the 
currents elicited by 300 µM kavain and 100 µM propofol were smaller than the 
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application of propofol alone (91 ± 1.5 % of the maximal propofol responses; n = 5; p < 
0.01; paired t test; Figure 4.10). 
 
Figure 4.9. Kavain modestly reduced etomidate potentiation, but did not affect the 
direct activation caused by etomidate at α1β2γ2L GABAARs. Top, Representative 
traces of current responses elicited by 10 mM GABA (control); 10 µM GABA; 10 µM 
GABA and 300 µM kavain; 10 µM GABA and 3 µM etomidate; 10 µM GABA, 300 µM 
kavain and 3 µM etomidate; 30 µM etomidate; 30 µM etomidate and 300 µM kavain. 
Bottom, Kavain caused a subtle but significant reduction in etomidate potentiation (G2 + 
E1 vs. G2 + K + E1; n = 7; p < 0.01; paired t test), but had no effect on etomidate activation 
(E2 vs. E2 + K; n = 6; p > 0.05; paired t test). Data are normalised to the 10 mM GABA 
responses, and are presented as mean ± SEM. 
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Figure 4.10. Kavain did not affect propofol potentiation, but modestly reduced 
propofol activation at α1β2γ2L GABAARs. Top, Representative traces of current 
responses to 10 mM GABA (control); 10 µM GABA; 10 µM GABA and 300 µM kavain; 
10 µM GABA and 10 µM propofol; 10 µM GABA, 300 µM kavain and 10 µM propofol. 
Middle, Continuous traces demonstrating two consecutive applications of control (100 
µM propofol) followed by the co-application of 300 µM kavain with control; and control. 
Bottom, Receptor modulation produced by propofol alone (G2 + P) was not significantly 
different from the combination of kavain and propofol (G2 + K + P; n = 5; p > 0.05; 
paired t test). The agonist effect of propofol (P2) was significantly reduced in the presence 
of kavain (P2 + K; n = 5; p < 0.01; paired t test). Data are presented as mean ± SEM. 
 
 
 
120 
 
 
4.3.5. Kavain activity at receptors containing α1M236W, β2M286W 
and β3N265M mutations 
One of the possible reasons for the inhibitory effect of kavain on the activity of 
anaesthetics is that kavain competes with these ligands for the same sites on GABAARs. 
However, given the lack of potency and efficacy of kavain, whether the nature of this 
inhibition is competitive could not be established. We hypothesised that if kavain binds 
to the same sites as etomidate and propofol, mutations in the β+α‒ transmembrane 
anaesthetic sites (α1M236W, β2M286W and β3N265M; Figure 4.11) which perturb 
etomidate and propofol actions would also affect kavain activity.  
 
 
Figure 4.11. The putative β+α‒ anaesthetic binding sites in a model structure of the 
α1β2γ2 GABAAR. The subunits are colour coded: α1, orange; β2, turquoise; γ2: green. 
(A) Side view of the receptor structure, with a close-up view of the three residues which 
are implicated in anaesthetic binding (inset): α1M236 (dark green), β2/3N265 (red) and 
β2/3M286 (dark blue). (B) Transmembrane region of the model structure with the 
extracellular domains removed for clarity, illustrating the positions of α1M236, β2/3N265 
and β2/3M286 residues. The arrangement of the TMDs (M1–M4) of an α1 and a β2 
subunit is illustrated. 
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4.3.5.1.  α1M236W 
The co-expression of α1M236W with β2 and γ2L subunits resulted in receptors with 
higher GABA potency (EC50 = 59 µM; n = 7) than wild-type α1β2γ2L GABAARs (EC50 
= 136 µM; p < 0.01 for logEC50 comparisons; unpaired t test; Figure 4.3; Table 4.3). The 
point mutation significantly attenuated the modulatory effects of 3 µM etomidate (p < 
0.0001; n = 5; unpaired t test; Figure 4.12) and 10 µM propofol (p < 0.01; n = 5; unpaired 
t test; Figure 4.12) on GABA EC3 (1 µM) responses. In contrast, the agonist effects of 
30 µM etomidate and 100 µM propofol appeared to be greater, but were not significantly 
different from wild-type receptors (p > 0.05; n = 5 for both etomidate and propofol; 
unpaired t test; Figure 4.12). Overall, these functional characteristics are consistent with 
previous studies [34].  
 
Next, we investigated the effect of kavain alone and in combination with GABA EC3 at 
α1M236Wβ2γ2L GABAARs. At 300 µM, kavain elicited current responses 
approximately 63 ± 5.2 % of the GABA EC3 responses (n = 6), which was significantly 
greater than that observed at wild-type receptors (15 ± 3.6 %; n = 4; p < 0.001; unpaired 
t test; Figure 4.14). The degree of potentiation produced by the co-application of GABA 
EC3 and 300 µM kavain, however, was not significantly different between α1β2γ2L (250 
± 7.8 % of GABA EC3 responses; n  = 4) and α1M236Wβ2γ2L (220 ± 11 %; n = 6) 
GABAARs (p > 0.05; unpaired t test).  
 
4.3.5.2.  β2M286W 
Receptors expressed from α1, β2M286W and γ2L subunits displayed enhanced GABA 
sensitivity (EC50 = 25 µM; n = 5; p < 0.0001 for logEC50 comparisons vs. α1β2γ2L; 
unpaired t test; Figure 4.3; Table 4.3). In agreement with previous studies, etomidate 
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sensitivity was abolished with the introduction of this point mutation, which is evident 
from the absence of modulatory and agonist effects (Figure 4.12) [34]. Receptor 
modulation produced by 10 µM propofol in the presence of GABA EC3 (1 µM) was also 
significantly diminished (p < 0.001; unpaired t test; Figure 4.12). However, the direct 
activation caused by 100 µM propofol was unaffected (p > 0.05; unpaired t test; Figure 
4.12). Similar propofol profile at α1β2M286Wγ2S receptors has been reported [35]. Like 
α1M236Wβ2γ2L, α1β2M286Wγ2L receptors showed increased efficacy in response to 
300 µM kavain alone (96 ± 5.8 % of the GABA EC3 responses; p < 0.0001; unpaired t 
test; Figure 4.14). The modulatory effect of kavain on GABA EC3-elicited current 
responses, however, was not significantly different from α1β2γ2L GABAARs (270 ± 8.7 
% of GABA EC3; p > 0.05; unpaired t test; Figure 4.14). 
 
4.3.5.3.  β3N265M 
The asparagine-to-methionine mutation at position 265 of the β2/3 subunits is known to 
profoundly weaken anaesthetic sensitivity with minimal effect on GABA activity (section 
1.11.3.5) [36, 37]. We found that GABA potencies at both α1β3γ2L and α1β3N265Mγ2L 
GABAARs were not significantly different (p > 0.05 for logEC50 comparisons; unpaired 
t test; Figure 4.3; Table 4.3). Etomidate did not modulate (at 3 µM) nor activate (at 30 
µM) the point-mutated receptors (Figure 4.13). Pronounced attenuation of propofol 
activity was also observed (Figure 4.13). In contrast to the α1M236W and β2M286W 
mutations, 300 µM kavain had negligible action by itself at α1β3N265Mγ2L receptors 
(3.3 ± 1.0 % of GABA EC3 responses). However, kavain modulation of GABA EC3 
responses was significantly reduced from 260 ± 18 % at α1β3γ2L to 110 ± 14 % at 
α1β3N265Mγ2L receptors (p < 0.001; unpaired t test; Figure 4.14). 
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Figure 4.12. Effect of α1M236W and β2M286W point mutations on etomidate and 
propofol sensitivity. (A) Representative traces demonstrating the modulatory effect of 3 
µM etomidate and 10 µM propofol on GABA EC3 (left) and the agonist effect of 30 µM 
etomidate and 100 µM propofol relative to 10 mM GABA (right) at α1β2γ2L, 
α1M236Wβ2γ2L, and α1β2M286Wγ2L GABAARs. (B) Etomidate and propofol 
modulation, but not activation were significantly reduced at α1M236Wβ2γ2L GABAARs. 
Both modulatory and agonist actions of etomidate were significantly diminished at 
α1β2M286Wγ2L GABAARs. Propofol modulation was also significantly weakened, 
while its agonist effect was unaffected. Data are normalised to current responses elicited 
by 10 mM GABA, and are presented as mean ± SEM. ** p < 0.01; *** p < 0.001; **** 
p < 0.0001; unpaired t test (mutants vs. wild-type). Numbers above bars indicate number 
of experiments. GABA + ETO: GABA EC3 + 3 µM etomidate; ETO: 30 µM etomidate; 
GABA + PRO: GABA EC3 + 10 µM propofol; PRO: 100 µM propofol. 
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Figure 4.13. The pronounced effect of β3N265M point mutation on etomidate and 
propofol sensitivity. (A) Representative traces demonstrating the modulatory effect of 3 
µM etomidate and 10 µM propofol on GABA EC3 (left) and the agonist effect of 30 µM 
etomidate and 100 µM propofol relative to 10 mM GABA (right) at α1β3γ2L and 
α1β3N265Mγ2L GABAARs. (B) The modulatory and agonist effects of etomidate and 
propofol were markedly diminished at α1β3N265Mγ2L GABAARs. Data are normalised 
to current responses elicited by 10 mM GABA, and are presented as mean ± SEM. *** p 
< 0.001; **** p < 0.0001; unpaired t test (mutant vs. wild-type). Numbers above bars 
indicate number of experiments. GABA + ETO: GABA EC3 + 3 µM etomidate; ETO: 30 
µM etomidate; GABA + PRO: GABA EC3 + 10 µM propofol; PRO: 100 µM propofol. 
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Figure 4.14. Effect of α1M236W, β2M286W and β3N265M point mutations on 
kavain activity. (A) Representative traces demonstrating current responses elicited by 
GABA EC3 (black bar), 300 µM kavain (red bar), and the combination of GABA EC3 and 
300 µM kavain at α1β2γ2L, α1M236Wβ2γ2L, α1β2M286Wγ2L, α1β3γ2L, and 
α1β3N265Mγ2L GABAARs. (B) Top, Kavain displayed increased agonist efficacy at 
α1M236Wβ2γ2L and α1β2M286Wγ2L GABAARs, but the combination of GABA EC3 
and kavain produced similar extent of potentiation compared to α1β2γ2L GABAARs. 
Bottom, Kavain modulatory action was significantly reduced at α1β3N265Mγ2L 
GABAARs. Data are normalised to GABA EC3 responses, and are presented as mean ± 
SEM. Numbers above bars indicate the number of experiments. Dotted lines indicate the 
current responses elicited by GABA EC3 alone. *** p < 0.001; **** p < 0.0001; unpaired 
t test (mutant vs. wild-type). Note: kavain-elicited current amplitudes were not deducted 
from the measurement of kavain-induced GABA potentiation. 
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4.4. Discussion 
In this study, we functionally characterised the effects of kavain at 9 different human 
GABAAR subtypes expressed in Xenopus oocytes, and found no subtype dependence in 
kavain potentiation (Figure 4.2C). The concentration-response relationships of kavain at 
all receptor subtypes investigated were steep, with no plateau obtained even at its 
solubility limit. Thus, we could not accurately determine the potency of kavain. The 
inference on the lack of subtype selectivity was based on the modulation efficacy of 
currents elicited by a low concentration of GABA by a maximal concentration of kavain 
(300 µM). Our results demonstrated that kavain potentiation did not require the α1 or γ2L 
subunit, as both β2γ2L and α1β2 GABAARs were modulated to similar extent as α1β2γ2L 
GABAARs. Furthermore, varying the α (α1, 2, 3 or 5) and β (β1, 2 or 3) subunit isoforms 
in αβγ2L receptors did not result in significant differences in kavain potentiation.  
 
However, kavain displayed functional differences at α1β2γ2L and α4β2δ GABAARs 
(Figure 4.4). Kavain modulated α1β2γ2L GABAARs at GABA concentrations below the 
EC45, but failed to potentiate peak GABA currents at higher concentrations. In contrast, 
the GABA concentration-response curve of α4β2δ GABAARs was significantly shifted 
upwards in the presence of kavain. The preference of kavain for α4β2δ GABAARs can be 
explained by the partial-agonist, weak-intrinsic-efficacy profile of GABA at this receptor 
subtype (section 1.11.1) that renders it more sensitive to kavain modulation. Similar 
differential enhancement effects that arise from the distinct GABA efficacies at synaptic 
αβγ and extrasynaptic αβδ receptors have been described for other allosteric ligands such 
as etomidate [38], propofol [39], pentobarbital [40], and neurosteroids [41]. While our 
findings do not conclusively prove that GABAARs are the in vivo substrate for kavain, it 
is tempting to speculate that kavain may have a larger impact on extrasynaptic than 
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synaptic GABAARs physiologically. This conjecture is substantiated by previous studies 
that found more prominent kavain or kavalactones actions in brain regions such as the 
hippocampus [21, 42], in which tonic GABAergic conductances mediated via δ-
containing GABAARs have been detected [43]. Future electrophysiological studies 
comparing kavain activity in neurons from wild-type and α4- or δ-knockout mice will be 
necessary to confirm this speculation. 
 
The low affinity of kavain detected in our study is in agreement with most studies 
conducted in the past using kava extracts or pure kavalactones [21, 22, 44]. The high-
micromolar concentrations required to observe the pharmacological actions of 
kavalactones in vitro raise the critical question of whether the concentrations used in these 
studies are indeed physiologically relevant. Studies conducted in mice showed that 100 
mg/kg of kavain alone caused a rapid surge in brain concentration (up to 100 µM) within 
minutes after i.p. injection [22, 45]. A higher brain concentration of kavain was found 
(120 µM) in the presence of other kavalactones (44 mg kavain in 120 mg/kg kavalactone 
mixture; i.p.), clearly demonstrating pharmacokinetic synergism [22, 45]. Davies et al. 
(1992) predicted higher brain concentrations (300 µM) with the administration of larger 
doses (300 mg/kg) of kavain [22]. Thus, kavain concentrations used in our study appear 
to correlate well with the concentrations needed to induce anxiolysis and hypnosis in mice 
[27, 46]. Unfortunately, the relevance of this concentration range cannot be established 
for humans as no data is currently available [47]. 
 
The possibility of kavalactones interacting non-specifically with lipid membrane of 
neurons to exert their psychoactive effects has been raised [21, 22]. This hypothesis is 
likely to stem from the historical Meyer-Overton theory which postulates that for a lipid-
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soluble anaesthetic agent, once a threshold number of dissolved molecules in lipid bilayer 
is reached, the physical distortion of neuronal membrane triggers changes in brain 
functions [48]. However, this theory has been contested and fallen out of favour, as 
converging lines of evidence obtained using electrophysiological, mutational, and mouse 
genetic approaches prove that anaesthetics do bind to distinct sites found on LGICs to 
directly exert their clinical effects [49]. Our mutational studies revealed a near-complete 
loss of kavain potentiation at α1β3N265Mγ2L GABAARs (Figure 4.14). The extensively 
studied β3N265M point mutation is known to selectively abolish the in vitro and in vivo 
sensitivity of anaesthetics such as etomidate, propofol, pentobarbital and volatile agents 
(section 1.11.3.5). As such, this finding argues strongly against the lipid hypothesis, and 
supports a direct kavain-GABAAR interaction.  
 
We also investigated the impact of mutating two homologous methionine residues 
(α1M236 and β2M286) that line the transmembrane β+α‒ anaesthetic binding sites 
(section 1.11.3.1). Substituting the methionine residues with tryptophan decreases 
etomidate and propofol sensitivity (Figure 4.12), an effect which has been correlated with 
increased side-chain volume of tryptophan sterically hindering anaesthetic binding [34]. 
Unlike β3N265M, the α1M236W and β2M286W point mutations did not negatively 
affect the activity of kavain (Figure 4.14), suggesting that either the binding determinants 
of kavain are different from etomidate and propofol, or kavain does not bind to the 
transmembrane β+α‒ interfaces. The enhanced agonist efficacy of kavain observed can 
be explained by the higher open probability of these spontaneously-gated mutant 
receptors [34].  
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We tentatively infer, based on the preliminary mutational evidence, that kavain binds to 
the transmembrane anaesthetic sites. Two observations support this notion: (1) The 
β3N265M point mutation impairs the sensitivity of anaesthetics agents that bind to 
homologous transmembrane cavities, but not benzodiazepines and neurosteroids which 
target binding sites of dissimilar locations (section 1.11.3.5). (2) Kavain displays a 
remarkably similar pharmacological profile to the volatile anaesthetics which exhibit low 
affinity (EC50 > 200 µM) and steep dose-response relationships, besides lacking subtype 
selectivity at GABAARs [50, 51]. Future investigation into the volatile anaesthetic 
determinants αS270 and αL277 [52]; other residues in the α+β‒, γ+β‒ and β+β‒ interfaces 
identified from photolabelling studies using anaesthetic analogues (section 1.11.3); and 
residues in other regions is warranted to provide a more comprehensive picture of kavain 
binding site(s). Given the absence of subtype specificity in kavain modulation at 
GABAARs, the existence of multiple binding sites for kavain is highly probable. 
 
As part of our efforts in characterising the interaction of kavain and other GABAAR 
modulators on a receptor level, we found that kavain action was not blocked by flumazenil 
(Figure 4.6). This finding corroborates previous studies that failed to detect any 
significant interaction of kavalactones with the high-affinity benzodiazepine site [19, 21-
23, 46]. In addition, kavain and diazepam modulated GABAARs in a less-than-additive 
manner, contrary to the speculated synergistic (supra-additive) interaction [30]. The co-
application of kavain and other GABAAR positive modulators such as allopregnanolone, 
DS2, etomidate and propofol also produced similar less-than-additive potentiation. 
Typically, two positive modulators that bind to distinct, independent binding sites give 
rise to additive potentiation when combined, as exemplified by sevoflurane and propofol 
[53], and diazepam and valerenic acid [54]. While the possibility of a competitive nature 
of these interactions cannot be denied, it seems unlikely that kavain binds to all the 
130 
 
 
implicated binding sites which are geographically distinct. It is more plausible that the 
putative kavain binding site(s) are allosterically coupled to these sites in an inhibitory 
fashion, resulting in less-than-additive joint enhancement. Alternatively, kavain may 
affect a common transduction pathway that reduces the enhancement efficacy by these 
modulators at GABAARs. It should be mentioned that most of these experiments were 
conducted with single ligand concentrations (with the exception of diazepam), and 
accurate determination of the nature of these interactions demands isobologram analysis. 
 
Despite the long history of kava consumption and the wealth of clinical evidence in favour 
of the efficacy of kavalactones in treating anxiety, there is a severe gap in our 
understanding of the molecular target(s) and the mechanism of action of these 
psychoactive compounds. The present study provides evidence that supports a direct 
interaction of kavain, the major kavalactone with GABAARs in vitro. The enhancement 
of GABAAR function by kavain occurs in a subtype-unselective and flumazenil-
insensitive manner, and the underlying mechanism may be similar to anaesthetic agents. 
Future studies comparing the behavioural responses of kavalactones in wild-type and 
mutant mice bearing the β3N265M point mutation will provide stronger evidence that 
GABAARs mediate the actions of kavalactones in vivo. Once this is established, the 
identification of specific GABAAR-enhancing kavalactones will give impetus in the 
development and refinement of these kava-derived chemicals as novel anxiolytics.  
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Chapter 5 
General discussion: Implications from the 
functional expression of βγ GABAARs 
______________________________________ 
 
Our work with the semi-synthetic flavonoid 2′MeO6MF revealed that the combination of 
the β3 and γ2L subunits formed fully functional receptors in Xenopus oocytes (Chapter 
3). Furthermore, depending on the injection ratios used, β3γ2L receptors showed unique 
pharmacological profile in response to GABA, 2′MeO6MF, etomidate and propofol, 
indicating the existence of multiple stoichiometric forms. We believe that the functional 
expression of βγ receptors has important implications, both in the study of GABAARs, as 
well as in drug discovery. We discuss these implications in more detail below. 
 
5.1. Flexibility in the subunit requirement of ligand binding 
sites 
One of the most striking aspects of βγ receptors is that it defies current understanding of 
GABAAR pharmacology. It lacks the α subunit which has been established to constitute 
the complementary faces of the GABA, etomidate and neurosteroid binding sites, as well 
as the principal face of the high-affinity benzodiazepine site (Chapter 1). Nevertheless, 
we and others have shown that βγ receptors are responsive to these ligands [1, 2]. While 
it is possible that hitherto unidentified binding sites are responsible for these responses, a 
more logical explanation would be alternative subunit interfaces harbouring homologous 
orthosteric and allosteric binding sites in these non-α-containing receptors. In other 
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words, the structural requirement for these binding sites may not be as strict as they are 
generally perceived. 
 
5.1.1.  GABA binding sites at the β+γ‒ interfaces? 
One of the possible explanations for the GABA sensitivity of βγ receptors is that the γ 
subunit can substitute for the α subunit to accommodate for GABA binding at the β+γ‒ 
and/or γ+β‒ interfaces. However, as the γ+β‒ interface is present in the αβγ receptors, 
and is not implicated in GABA binding [3], the β+γ‒ interface is a more plausible 
candidate. The conventional β+α‒ interface has an “aromatic box” formed by βY97, 
βY157, βF200, βY205, and αF64 residues which is essential in agonist recognition 
(Figure 1.8B) [4-6]. The integrity of this aromatic box is likely to be maintained at the 
β+γ‒ interfaces, as the homologous residue in the γ subunit that corresponds to αF64 is 
also a phenylalanine (γF77; Figure 5.1).  
 
 
Figure 5.1. Aligned sequence of the α1 subunit that forms the complementary face 
of the GABA binding site, and the corresponding region in the γ2 subunit (which 
forms the complementary face of the benzodiazepine site). Residues important for 
binding or function of orthosteric ligands are highlighted in red, whereas the residues 
implicated in benzodiazepine sensitivity are highlighted in turquoise. Residue α1F64 
(indicated by *) is an important determinant of GABA binding and gating. Homology 
modelling predicts α1R66 (indicated by ‡) to form salt bridges, and α1T129 (indicated 
by §) to form hydrogen bonds with GABA. The sequence numbering is based on the 
alignment presented in Bergmann et al. (2013) [4]. The secondary structures indicated 
below the sequence are based on the X-ray crystal structure of the human β3 homomeric 
GABAAR [7]. 
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Furthermore, other α subunit residues implicated in GABA binding/function such as 
α1L127, α1T129 (predicted to form a hydrogen bond with GABA) and α1R131 are 
conserved at the corresponding positions in the γ2 subunit, except for α1R66. As α1R66 
was predicted to form salt bridges with GABA by Bergmann et al. (2013) [4], we 
postulate that this interaction is not possible in βγ receptors as the bidentate arginine is 
replaced with a non-polar alanine residue in the γ2 subunit (γ2A79), which may underlie 
the > 100-fold lower GABA potency at β2γ2L compared to α1β2 receptors (Figure 4.3, 
Table 4.3). Hence, it is of interest to investigate whether the γ2A79R mutation will 
enhance GABA sensitivity of βγ receptors to resemble that of αβ or αβγ receptors. Besides 
that, mutational studies targeting residues found on the β+γ‒ interfaces which correspond 
to those found in the β+α‒ GABA binding sites will help establish the existence of GABA 
binding sites at βγ receptors. 
 
5.1.2.   High-affinity benzodiazepine site at the β+γ‒ interface? 
The possibility for the β subunit to form the high-affinity benzodiazepine site with the γ 
subunit in the absence of the α subunit was suggested following the discovery that 
diazepam modulated α1β2γ2 and β2γ2 receptors to similar extent in several studies 
(Figure 5.2A and B) [1, 2, 8]. In concordance with these findings, we also detected 
diazepam potentiation at β2γ2L receptors (Figure 5.2C). As part of the effort to identify 
the binding determinants of diazepam, Amin et al. (1997) showed that mutating two 
tyrosine residues in the principal face of the α1 subunit (α1Y159 and α1Y209) to serine 
significantly diminished diazepam sensitivity at α1β2γ2 receptors [2]. In contrast, when 
the corresponding conserved tyrosine residues in the γ2 subunit were mutated to serine 
(γ2Y172S and γ2Y220S), modest reduction in diazepam modulation was detected at 
α1β2γ2Y172S and α1β2γ2Y220S receptors. These mutations had no effects on diazepam 
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action at β2γ2Y172S and β2γ2Y220S receptors [2]. Based on these findings, we infer that 
the principal face of the γ2 subunit (i.e., γ+β‒ or γ+γ‒ interfaces) is unlikely to mediate 
diazepam modulation at the non-α-containing β2γ2 receptors.  
 
While it is possible for the β+γ‒ interface to hold the benzodiazepine site, ascertaining 
this binding interface is expected to be challenging because residues found in the principal 
face of the β subunit (e.g., β2Y157 and β2Y205) are also involved in GABA binding 
(Figure 5.2D). As such, mutations in this region will inevitably attenuate GABA 
sensitivity, which will complicate the interpretation of changes to diazepam’s GABA-
modulatory action. Additionally, as we have proposed that the β+γ‒ interfaces to be the 
site of GABA action for βγ receptors, it is mechanistically unclear as to how diazepam 
can modulate these receptors via the same sites in the presence of GABA. Having said 
that, it is not impossible for benzodiazepines to bind to the GABA binding sites, as such 
possibility has recently been highlighted for flurazepam and zopiclone [9]. 
 
The α1H101 residue plays an integral role in diazepam sensitivity, and mutations of this 
residue greatly reduce diazepam affinity at α1βγ2 receptors (section 1.11.2.1). Thus, it is 
questionable that the non-conservative substitution of histidine with leucine at residue 99 
in the β2 subunit (β2L99; Figure 5.2D) will confer high-affinity diazepam binding 
through the β+γ‒ interfaces. Despite the absence of this critical binding residue, diazepam 
potentiates β2γ2 receptors at nanomolar-to-low-micromolar concentrations. While a 
detailed mutational study is warranted to elucidate the mechanism underlying diazepam 
sensitivity at these α-lacking receptors, a possible explanation is that diazepam’s contact 
points at βγ receptors are different from those determined at αβγ receptors. This 
hypothesis is supported by the considerable variability reported previously for the binding 
138 
 
 
determinants of (1) different benzodiazepine site ligands in the α1+γ2‒ interface [10], and 
(2) the same ligand in different αx+γ2‒ (x = 1, 2, 3, 5 or 6) interfaces [11]. 
  
 
Figure 5.2. Diazepam potentiation at β2γ2 GABAARs. Comparable diazepam actions 
at α1β2γ2 and β2γ2 GABAARs reported by (A) Whittemore et al. (1996) and (B) Amin 
et al. (1997). (B) The γ2Y172S and γ2Y220S point mutations had not effect on diazepam 
activity at β2γ2 receptors. The corresponding mutations in the α1 subunit significantly 
reduced diazepam potentiation at α1β2γ2 receptors. (C) Continuous traces demonstrating 
the application of control (10 µM GABA); control and 1 µM diazepam; followed by two 
consecutive applications of control at β2γ2L (1:20) receptors (n = 4). (D) Aligned 
sequence of the α1 subunit that forms the principal face of the benzodiazepine binding 
site, and the corresponding region in the β2 subunit (which line the principal face of the 
orthosteric site). Residues important for binding or function of benzodiazepines are 
highlighted in turquoise, whereas the residues implicated in GABA actions are 
highlighted in red. Residue α1H101 (indicated by *) is an important in vitro and in vivo 
determinant for diazepam (section 1.11.2.1). Homology modelling predicts α1Y159 
(indicated by ‡), α1T206 (indicated by §) and α1Y209 (indicated by ¶) to form polar 
contacts with diazepam. The sequence numbering is based on the alignment presented in 
Bergmann et al. (2013) [4]. The secondary structures indicated below the sequence are 
based on the X-ray crystal structure of the human β3 homomeric GABAAR [7]. 
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5.1.3. Other allosteric binding sites 
Besides GABA and diazepam, we and others have shown that many allosteric ligands 
such as etomidate, propofol, loreclezole, pentobarbital, 3α-hydroxy-5α-pregnan-20-one 
(3α,5α-P) and mefenamic acid also have comparable actions at αβγ and βγ receptors 
(Figure 5.3) [1, 12]. These functional data reflect that homologous ligand binding sites 
may exist in βγ receptors, but may not have been detected in αβ or αβγ receptors 
previously. In keeping with this postulation, evidence from photoaffinity labelling studies 
demonstrated that homologous transmembrane anaesthetic binding sites do exist at 
distinct subunit interfaces (β+α‒, α+β‒, γ+β‒, or β+β‒) depending on the GABAAR 
subtypes investigated (section 1.11.3).    
 
 
Figure 5.3. Comparable actions of various allosteric ligands at αβγ and βγ 
GABAARs. (A) Modulatory effects of pentobarbital (PB), 3α-hydroxy-5α-pregnan-20-
one (3α,5α-P), mefenamic acid (MA), and loreclezole (LZ) reported by Whittemore et al. 
(1996) [1]. (B) Direct activation of α1β2γ2S and β2γ2S receptors by propofol and its 
derivative 4-iodo-2,6-diisopropylphenol (4-I-Pro) reported by Sanna et al. (1999) [12]. 
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5.2. Possibility of mixed βγ and αβγ GABAARs 
A common problem in the heterologous expression of recombinant GABAARs is the 
presence of mixed αβ and αβγ receptor populations which compromises the accuracy in 
measuring a receptor property of interest. To circumvent this problem, an injection ratio 
which is heavily biased toward the γ2 subunit is usually used when expressing αβγ 
receptors in Xenopus oocytes. Boileau et al. (2002) found that an injection ratio of 1:1:10 
for α1:β2:γ2 subunit mRNAs was necessary to produce “a purer population of α1β2γ2 
receptors” characterised by a lower GABA potency (~4-fold) than α1β2 (1:1) receptors 
(Figure 5.4A), and consistent measurement of diazepam potentiation [13]. However, 
studies conducted by Baburin et al. (2008) showed that while increasing the relative 
amount of the γ subunit resulted in greater degree of diazepam potentiation, a great 
portion of αβ receptors was still present even at a 1:1:20 ratio, contributing to the 
discrepancy in GABA potency measured at α1β2γ2 receptors formed from free subunits 
and concatenated constructs (Figure 5.4B) [14].  
 
In contrast to these studies, under our experimental conditions, we found that an injection 
ratio of 1:1:2 (α2:β2:γ2L) reduced the GABA potency approximately 7 fold compared to 
α2β2 (1:1) receptors (Figure 5.4C). Increasing the ratio to 1:1:10 resulted in ~55-fold 
decrease in GABA potency, and the concentration-response curve displayed a low Hill 
slope (nH = 0.73). Notably, the GABA concentration-response curve of α2β2γ2L (1:1:10) 
receptors overlaps with that of β2γ2L (1:10) receptors, raising a cautionary note on the 
possibility of mixed βγ and αβγ populations. This hypothesis, however, will be difficult 
to test as both αβγ and βγ receptors are potentiated by diazepam (Figure 5.2) and are 
insensitive to Zn2+ inhibition (Figure 5.5), thus precluding these compounds as diagnostic 
tools. Nevertheless, based on these studies, it is clear that a one-ratio-fits-all solution does 
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not exist, and the ratio chosen needs to be tailored according to experimental parameters 
such as the quality of mRNA, the plasmid vector, the origin of subunit cDNAs and the 
subunit splice variants, as well as pharmacological evidence. 
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Figure 5.4. GABA concentration-response curves of αβ, αβγ, and βγ GABAARs 
expressed in Xenopus oocytes using different injection ratios from pharmacological 
studies. The curve parameters are summarised in tables on the right panel. Figures were 
taken from (A) Boileau et al. (2002) [13], (B) Baburin et al. (2008) [14], and (C) the 
present study. 
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Figure 5.5. Zn2+ sensitivity at α1β2, β2γ2L and α1β2γ2L receptors. Current traces 
demonstrating the co-application of 10 µM Zn2+ with a GABA concentration close to 
EC50. Zn
2+ inhibits the GABA-elicited current at α1β2 receptors (n = 8), but has no effects 
at β2γ2L (n = 5) and α1β2γ2L (n = 9) receptors. 
 
5.3. Perspective 
To our knowledge, there are at least 15 studies to date (excluding the present study) that 
have demonstrated the in vitro functional expression of βγ receptors [1, 2, 8, 12, 15-25]. 
Despite this level of evidence, βγ receptors are still not routinely used as a tool receptor 
in pharmacological studies, perhaps due to (1) the reluctance to accept the evidence for 
its formation as it contradicts the general consensus that only the αβ and αβγ combinations 
can access cell surface efficiently to form functional receptors; (2) the questionable 
physiological existence of βγ receptors; and/or (3) the “erratic” nature of βγ receptors 
reported by some studies [23]. Majority of studies have in the past inferred the subunit 
requirement of a chemical of interest’s binding site(s) based on its activity at recombinant 
αβ and αβγ receptors, and mutational studies designed based on these data had led to the 
identification of binding/function determinants.  
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In our view, this approach is incomplete and potentially misleading. The heteromeric 
nature of GABAARs, coupled with the interfacial nature of most ligand binding sites 
necessitate pharmacological analysis of different receptor subtypes to fully understand 
the subunit requirement for a ligand of interest. For these reasons, we believe that the 
inclusion of βγ receptors in pharmacological studies will provide a more comprehensive 
picture of a ligand binding site, besides preventing the overestimation of a ligand’s 
subtype selectivity. It is worth mentioning at this stage that the recent work of Maldifassi 
et al. (2016) provided evidence that etomidate, propofol and pentobarbital interact with 
the γ+β‒ interface in α1β2γ2 receptors [26]. This finding does not come as a surprise as 
these ligands have all been shown to be functional at βγ receptors.  
 
The fact that we observed pharmacological differences with β3γ2L GABAARs expressed 
using different injection ratios (Chapter 3) adds another layer of complexity to this 
discussion.  However, as the experimental approaches used in our study do not provide 
direct evidence that distinct subunit stoichiometries contribute to the remarkable 
variability in the pharmacology of β3γ2L GABAARs, the use of concatenated constructs 
in the future will be necessary to confirm our findings. Nevertheless, the functional data 
obtained using 2′MeO6MF (Figure 3.5) clearly show that non-optimal injection ratios 
not only cause receptors of different subunit composition to be expressed, but mixed 
stoichiometric forms of the same receptor subtype could also affect the accuracy of 
pharmacological studies. 
 
In conclusion, there is now strong evidence indicating more complex GABAAR 
pharmacology than previously anticipated. Hence, it is of utmost importance that future 
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drug discovery and structure-function analysis efforts using recombinant receptors to be 
designed and interpreted with this level of complexity in mind. 
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Chapter 6 
GABAARs as the molecular target for 
kavalactones: Future directions 
______________________________________ 
 
It has almost been 30 years since GABAARs were first proposed to mediate the in vivo 
effects of kavalactones. However, a lack in robust experimental evidence has led to 
ambiguity in the explication of a GABAergic mechanism for these natural products. In a 
pharmacological study conducted using kavain as a representative kavalactone on a range 
of human recombinant GABAAR subtypes expressed in Xenopus oocytes, we 
demonstrated that kavain directly potentiated GABAARs with no subtype selectivity 
(Chapter 4). We also presented evidence that kavain potentiation did not occur via the 
high-affinity benzodiazepine binding site, and the underlying mechanism of kavain may 
be common to the GABAAR-targeting anaesthetics. While these findings are 
encouraging, many aspects of kavalactone actions at GABAARs remain to be explored.  
 
6.1. Effect of enantiomerically pure kavain 
With the exception of the achiral yangonin and desmethoxyangonin, other major 
kavalactones such as kavain, dihydrokavain, methysticin and dihydromethysticin have a 
stereocenter, and only the (+)-enantiomer forms occur naturally (Figure 4.1). Despite the 
homochirality, majority of the studies investigating the in vitro and in vivo effects of 
individual kavalactones have used the racemic mixture, as it is the only commercially 
available form. For the same reason, (±)-kavain (or DL-kavain) was used in our study. 
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However, given the precedents for chiral ligands to exhibit opposite modulatory effects 
at GABAARs [1], the possibility of (-)-kavain confounding the determination of (+)-
kavain pharmacology should not be excluded. The pharmacological characterisation of 
(+)-kavain obtained through chemical synthesis [2] or chromatographic isolation [3] in 
the future will provide further insight into the structure-activity relationship of kavain 
activity at GABAARs. 
 
6.2. Potential for synergistic modulation of kavalactones  
A synergistic pharmacodynamic interaction of kavalactones has been suspected as the 
pharmacological activity of kava extracts is usually greater than individual kavalactones 
[4]. We have preliminary data indicating comparable GABA enhancement effects by 
yangonin, methysticin and dihydromethysticin to kavain at α1β2γ2L GABAARs (data not 
shown). Hence, future studies investigating the effects of these kavalactones in different 
combinations (pairs, triplets, or quadruplets) will help clarify the nature of their 
interactions, as well as identifying the most efficacious kavalactone combination(s) at 
GABAARs. 
 
6.3. Effect of kavalactones in transgenic mice 
The use of knock-in mice bearing the β3N265M point mutation has aided the 
establishment of GABAARs as one of the major in vivo targets of general anaesthetics 
(section 1.11.3) [5]. Our mutational studies clearly demonstrated that the β3N265M 
mutation strongly impaired kavain potentiation in vitro. We expect that the analysis of 
kavalactones in the transgenic mouse line will allow us to correlate any attenuated 
behavioural responses with GABAARs containing the mutant β3 subunit. While 
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speculative, we do not think that the transgenic mice will be completely resistant to 
kavalactones-induced responses as other targets (different GABAAR subtypes or other 
receptors/enzymes) may also contribute to the in vivo effects of kavalactones. 
Nevertheless, a moderate reduction in behavioural response(s), together with evidence 
from electrophysiological and mutational studies will provide more definitive evidence 
that specific GABAAR subtypes do mediate kavalactone actions. 
 
6.4. Concluding remarks 
The findings from clinical trials on the efficacy of medically-prescribed kava extracts 
containing standardised, enriched kavalactones in the treatment of anxiety are 
encouraging. Besides alleviating the debilitating symptoms associated with anxiety, kava 
shows no tolerance, addictive and withdrawal tendencies [6]. Together with the mild-to-
negligible side effects reported in these human studies [7, 8], the presumed bioactive 
constituent kavalactones are attractive novel anxiolytics. However, as with most natural 
products, the effective clinical use of kavalactones suffers from the lack of understanding 
of their biological targets. Our pharmacological study with kavain provides evidence that 
the naturally-abundant kavalactone directly enhances GABAAR function. These findings 
serve as a starting point for future target-validation studies.  
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